Obstructive Sleep Apnea: Epidemiology, Pathophysiology, Complications, Diagnosis, Management, and Emerging Fibrosis-Linked Remodeling

Abstract

Obstructive sleep apnea (OSA) is a highly prevalent yet substantially underdiagnosed sleep-related breathing disorder increasingly recognized as a heterogeneous systemic disease rather than a purely mechanical consequence of recurrent upper-airway collapse. This review provides an updated and integrated overview of OSA, spanning epidemiology, multifactorial pathophysiology, heterogeneous clinical presentation, major cardiometabolic and end-organ consequences, diagnostic principles, and evolving personalized management, while also emphasizing the limitations of conventional severity classification, which is predominantly based on the apnea–hypopnea index. We highlight how intermittent hypoxia–reoxygenation, sleep fragmentation, sympathetic activation, intrathoracic pressure stress, endothelial dysfunction, inflammation, oxidative stress, and metabolic dysregulation interact to drive systemic injury, and why physiologically enriched metrics such as hypoxic burden, T90, event duration, sleep-stage dependency, and endotypic heterogeneity may better capture biological risk than event frequency alone. Within this broader framework, fibrosis-linked structural remodeling emerges as an important yet under-supported dimension of OSA pathobiology. Experimental and clinical evidence suggests that OSA may contribute to remodeling of the lungs, liver, kidneys, and heart, although the strength of the evidence and the degree of causal inference vary across organs. By integrating established knowledge with this emerging fibrosis-oriented perspective, this review defines key mechanistic, diagnostic, and translational priorities for future research and phenotype-aware clinical stratification.

Keywords

fibrosis / hypoxic burden / intermittent hypoxia / obstructive sleep apnea / organ remodeling / personalized management

References

[1] A. V. Benjafield, N. T. Ayas, P. R. Eastwood, et al., “Estimation of the Global Prevalence and Burden of Obstructive Sleep Apnoea: A Literature-based Analysis,” The Lancet Respiratory Medicine 7, no. 8 (2019): 687–698.

[2] G. Iannella, A. Pace, M. G. Bellizzi, et al., “The Global Burden of Obstructive Sleep Apnea,” Diagnostics 15, no. 9 (2025): 1088.

[3] V. Kapur, K. P. Strohl, S. Redline, C. Iber, G. O'Connor, and J. Nieto, “Underdiagnosis of Sleep Apnea Syndrome in U.S. Communities,” Sleep & Breathing = Schlaf & Atmung 06, no. 2 (2002): 049–054.

[4] T. Young, L. Evans, L. Finn, and M. Palta, “Estimation of the Clinically Diagnosed Proportion of Sleep Apnea Syndrome in Middle-aged Men and Women,” Sleep 20, no. 9 (1997): 705–706.

[5] S. Redline, A. Azarbarzin, and Y. Peker, “Obstructive Sleep Apnoea Heterogeneity and Cardiovascular Disease,” Nature Reviews Cardiology 20, no. 8 (2023): 560–573.

[6] C. Coso, E. Solano-Pérez, S. Romero-Peralta, et al., “The Hypoxic Burden, Clinical Implication of a New Biomarker in the Cardiovascular Management of Sleep Apnea Patients: A Systematic Review,” Reviews in Cardiovascular Medicine 25, no. 5 (2024): 172.

[7] A. Parekh, K. Kam, S. Wickramaratne, et al., “Ventilatory Burden as a Measure of Obstructive Sleep Apnea Severity Is Predictive of Cardiovascular and all-Cause Mortality,” American Journal of Respiratory and Critical Care Medicine 208, no. 11 (2023): 1216–1226.

[8] G. Labarca, D. Vena, W. H. Hu, et al., “Sleep Apnea Physiological Burdens and Cardiovascular Morbidity and Mortality,” American Journal of Respiratory and Critical Care Medicine 208, no. 7 (2023): 802–813.

[9] R. D. McEvoy, N. A. Antic, E. Heeley, et al., “CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea,” New England Journal of Medicine 375, no. 10 (2016): 919–931.

[10] A. Azarbarzin, D. Vena, N. Esmaeili, et al., “Cardiovascular Benefit of Continuous Positive Airway Pressure According to High-risk Obstructive Sleep Apnoea: A Multi-trial Analysis,” European Heart Journal 47, no. 17 (2026): 2077–2089, Published online August 5, 2025:ehaf447.

[11] D. R. Mazzotti, U. J. Magalang, B. T. Keenan, et al., “OSA Symptom Subtypes and Hypoxic Burden Independently Predict Distinct Cardiovascular Outcomes,” ERJ Open Research 11, no. 1 (2025): 00511–02024.

[12] S. Javaheri, S. Javaheri, V. K. Somers, et al., “Interactions of Obstructive Sleep Apnea with the Pathophysiology of Cardiovascular Disease, Part 1,” Journal of the American College of Cardiology 84, no. 13 (2024): 1208–1223.

[13] Y. Yeghiazarians, H. Jneid, J. R. Tietjens, et al., “Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement from the American Heart Association,” Circulation 144, no. 3 (2021): e56–e67.

[14] W. T. McNicholas and H. Korkalainen, “Translation of Obstructive Sleep Apnea Pathophysiology and Phenotypes to Personalized Treatment: A Narrative Review,” Frontiers in Neurology 14 (2023): 1239016.

[15] R. Lv, X. Liu, and Y. Zhang, Pathophysiological Mechanisms and Therapeutic Approaches in Obstructive Sleep Apnea Syndrome (Springer US, 2023).

[16] R. Song, T. L. Baker, J. J. Watters, and S. Kumar, “Obstructive Sleep Apnea-Associated Intermittent Hypoxia-Induced Immune Responses in Males, Pregnancies, and Offspring,” International Journal of Molecular Sciences 25, no. 3 (2024): 1852.

[17] S. Naushad, J. Gaucher, Z. Mezdari, et al., “Chronic Intermittent Hypoxia Triggers Cardiac Fibrosis: Role of Epididymal White Adipose Tissue Senescent Remodeling?,” Acta Physiologica (Oxford, England) 240, no. 11 (2024): e14231.

[18] M. Liang, L. Si, Z. Yu, et al., “Intermittent Hypoxia Induces Myofibroblast Differentiation and Extracellular Matrix Production of MRC5s via HIF-1α-TGF-β/Smad Pathway,” Sleep & Breathing = Schlaf & Atmung 28, no. 1 (2024): 291–300.

[19] S. Han, J. Huang, C. Yang, J. Feng, and Y. Wang, “The Histone Demethylase KDM6B Links Obstructive Sleep Apnea to Idiopathic Pulmonary Fibrosis,” Faseb Journal 39, no. 1 (2025): e70306.

[20] M. Xiong, Y. Zhao, H. Mo, H. Yang, F. Yue, and K. Hu, “Intermittent Hypoxia Increases ROS/HIF-1α 'related Oxidative Stress and Inflammation and Worsens Bleomycin-induced Pulmonary Fibrosis in Adult Male C57BL/6J Mice,” International Immunopharmacology 100 (2021): 108165.

[21] H. He, Z. Zhou, L. Zhang, Z. Lu, B. Li, and X. Li, “HIF1α/MIF/CD74 Signaling Mediated OSA-induced Atrial Fibrillation by Promoting M1 Macrophages Polarization,” International Immunopharmacology 149 (2025): 114248.

[22] C. R. Wei, I. Jalali, J. Singh, et al., “Exploring the Prevalence and Characteristics of Obstructive Sleep Apnea among Idiopathic Pulmonary Fibrosis Patients: A Systematic Review and Meta-Analysis,” Cureus 16, no. 2 (2024): e54562, Published online February 20, 2024.

[23] L. Wang, H. Liu, L. Zhou, et al., “Association of Obstructive Sleep Apnea With Nonalcoholic Fatty Liver Disease: Evidence, Mechanism, and Treatment,” NSS 16 (2024): 917–933.

[24] C. J. Zhang, H. Li, Y. Z. Xiong, et al., “Chronic Intermittent Hypoxia Induces Renal Fibrosis Through MR Activation,” Experimental Gerontology 163 (2022): 111780.

[25] J. Bordas-Martinez, N. Salord, V. Vicens-Zygmunt, et al., “Treating Sleep-disordered Breathing of Idiopathic Pulmonary Fibrosis Patients With CPAP and Nocturnal Oxygen Treatment. A Pilot Study : Sleep-disordered Breathing Treatment in IPF,” Respiratory Research 25, no. 1 (2024): 247.

[26] T. V. Channapragada, C. R. Brenner, K. Guruswamy, et al., “Does Continuous Positive Airway Pressure Improve Liver Outcomes in MASLD With Obstructive Sleep Apnea? A Systematic Review,” JCM 15, no. 1 (2025): 225.

[27] E. Zamarrón, A. Jaureguizar, A. García-Sánchez, et al., “Continuous Positive Airway Pressure Effect on Albuminuria Progression in Patients With Obstructive Sleep Apnea and Diabetic Kidney Disease: A Randomized Clinical Trial,” American Journal of Respiratory and Critical Care Medicine 207, no. 6 (2023): 757–767.

[28] R. B. Berry, R. Brooks, C. Gamaldo, et al., “AASM Scoring Manual Updates for 2017 (Version 2.4),” Journal of Clinical Sleep Medicine 13, no. 5 (2017): 665–666.

[29] B. Duce, J. Milosavljevic, and C. Hukins, “The 2012 AASM Respiratory Event Criteria Increase the Incidence of Hypopneas in an Adult Sleep Center Population,” Journal of Clinical Sleep Medicine 11, no. 12 (2015): 1425–1431.

[30] C. Hirotsu, J. Haba-Rubio, D. Andries, et al., “Effect of Three Hypopnea Scoring Criteria on OSA Prevalence and Associated Comorbidities in the General Population,” Journal of Clinical Sleep Medicine 15, no. 2 (2019): 183–194.

[31] W. R. Ruehland, P. D. Rochford, F. J. O'Donoghue, R. J. Pierce, P. Singh, and A. T. Thornton, “The New AASM Criteria for Scoring Hypopneas: Impact on the Apnea Hypopnea Index,” Sleep 32, no. 2 (2009): 150–157.

[32] L. D. J. Thomson, S. A. Landry, R. Singleton, et al., “The Effect of Hypopnea Scoring on the Arousal Threshold in Patients With Obstructive Sleep Apnea,” American Journal of Respiratory and Critical Care Medicine 202, no. 9 (2020): 1308–1311.

[33] C. A. Chou, A. Khan, and A. Singh, “The Impact of 4% versus 3% Hypopnea Scoring Criteria on Obstructive Sleep Apnea Diagnosis in Women: A Scoping Review and Commentary,” Sleep Science Practice 9, no. 1 (2025): 29.

[34] P. Cushman, A. Radtke, J. Kang, et al., “Modified Scoring Criteria to Improve the Accuracy of the Home Sleep Apnea Test,” Sleep & Breathing = Schlaf & Atmung 30, no. 1 (2026): 52.

[35] M. Pitkänen, R. K. Nath, H. Korkalainen, et al., “Respiratory Event Index Underestimates Severity of Sleep Apnea Compared to Apnea-hypopnea Index,” Sleep Advances 5, no. 1 (2024): zpad054.

[36] B. Lechat, G. Naik, A. Reynolds, et al., “Multinight Prevalence, Variability, and Diagnostic Misclassification of Obstructive Sleep Apnea,” American Journal of Respiratory and Critical Care Medicine 205, no. 5 (2022): 563–569.

[37] B. Lechat, H. Scott, J. Manners, et al., “Multi-night Measurement for Diagnosis and Simplified Monitoring of Obstructive Sleep Apnoea,” Sleep Medicine Reviews 72 (2023): 101843.

[38] T. Young, M. Palta, J. Dempsey, J. Skatrud, S. Weber, and S. Badr, “The Occurrence of Sleep-Disordered Breathing Among Middle-Aged Adults,” New England Journal of Medicine 328, no. 17 (1993): 1230–1235.

[39] P. Balagny, E. Vidal-Petiot, A. Renuy, et al., “Prevalence, Treatment and Determinants of Obstructive Sleep Apnoea and Its Symptoms in a Population-based French Cohort,” ERJ Open Research 9, no. 3 (2023): 00053–02023.

[40] H. Strongman, M. Sykorova, Y. T. N. Yu, et al., “Incidence and Prevalence of Obstructive Sleep Apnoea and Narcolepsy in the UK: A Population-based Descriptive Study,” Thorax 0 (2026): 1–14.

[41] U. Rehman, Y. Ahn, E. Yerushalmi, et al., “Neglected Burden of Obstructive Sleep Apnoea: Workplace Productivity Loss in the USA and UK,” Thorax 81, no. 5 (2026): 492–494.

[42] M. M. Lyons, N. Y. Bhatt, A. I. Pack, and U. J. Magalang, “Global Burden of Sleep-disordered Breathing and Its Implications,” Respirology 25, no. 7 (2020): 690–702.

[43] T. M. Suri, T. Ghosh, S. Mittal, V. Hadda, K. Madan, and A. Mohan, “Systematic Review and Meta-analysis of the Prevalence of Obstructive Sleep Apnea in Indian Adults,” Sleep Medicine Reviews 71 (2023): 101829.

[44] Y. Niu, S. Sun, Y. Wang, L. Chen, Y. Shao, and X. Zhang, “Spatiotemporal Trends in the Prevalence of Obstructive Sleep Apnoea across China: A Multilevel Meta-Analysis Incorporating Geographic and Demographic Stratification (2000-2024),” Nature and Science of Sleep 17 (2025): 879–903.

[45] I. Sönmez, A. Vo Dupuy, K. S. Yu, J. Cronin, J. Yee, and A. Azarbarzin, “Unmasking Obstructive Sleep Apnea: Estimated Prevalence and Impact in the United States,” Respiratory Medicine 248 (2025): 108348.

[46] E. Boers, M. A. Barrett, A. V. Benjafield, et al., “Projecting the 30-year Burden of Obstructive Sleep Apnoea in the USA: A Prospective Modelling Study,” Lancet Respiratory Medicine 13, no. 12 (2025): 1078–1086.

[47] R. Heinzer, S. Vat, P. Marques-Vidal, et al., “Prevalence of Sleep-disordered Breathing in the General Population: The HypnoLaus Study,” The Lancet Respiratory Medicine 3, no. 4 (2015): 310–318.

[48] P. E. Peppard, T. Young, J. H. Barnet, M. Palta, E. W. Hagen, and K. M. Hla, “Increased Prevalence of Sleep-Disordered Breathing in Adults,” American Journal of Epidemiology 177, no. 9 (2013): 1006–1014.

[49] C. V. Senaratna, J. L. Perret, C. J. Lodge, et al., “Prevalence of Obstructive Sleep Apnea in the General Population: A Systematic Review,” Sleep Medicine Reviews 34 (2017): 70–81.

[50] I. Fietze, N. Laharnar, A. Obst, et al., “Prevalence and Association Analysis of Obstructive Sleep Apnea With Gender and Age Differences—Results of SHIP-Trend,” Journal of Sleep Research 28, no. 5 (2019): e12770.

[51] R. S. Osorio, M. Á. Martínez-García, and D. M. Rapoport, “Sleep Apnoea in the Elderly: A Great Challenge for the Future,” European Respiratory Journal 59, no. 4 (2022): 2101649.

[52] K. Zasadzińska-Stempniak, H. Zajączkiewicz, and A. Kukwa, “Prevalence of Obstructive Sleep Apnea in the Young Adult Population: A Systematic Review,” JCM 13, no. 5 (2024): 1386.

[53] T. Ghavami, M. Kazeminia, N. Ahmadi, and F. Rajati, “Global Prevalence of Obstructive Sleep Apnea in the Elderly and Related Factors: A Systematic Review and Meta-Analysis Study,” Journal of PeriAnesthesia Nursing 38, no. 6 (2023): 865–875.

[54] E. O. Bixler, A. N. Vgontzas, H. M. Lin, et al., “Sleep Disordered Breathing in Children in a General Population Sample: Prevalence and Risk Factors,” Sleep 32, no. 6 (2009): 731–736.

[55] S. Magnusdottir and E. A. Hill, “Prevalence of Obstructive Sleep Apnea (OSA) Among Preschool Aged Children in the General Population: A Systematic Review,” Sleep Medicine Reviews 73 (2024): 101871.

[56] I. Ingolfsdottir, L. Hrolfsdottir, G. B. Johannesdottir, et al., “Obstructive Sleep Apnea in Children: Prevalence and Association With Overweight and Obesity,” Front Sleep 4 (2026): 1691091.

[57] Y. Wang, H. Liu, B. Zhou, W. Yue, M. Wang, and K. Hu, “Menopause and Obstructive Sleep Apnea: Revealing an Independent Mediating Role of Visceral Fat Beyond Body Mass Index,” BMC Endocrine Disorders 25, no. 1 (2025): 21.

[58] T. Young, L. Finn, D. Austin, and A. Peterson, “Menopausal Status and Sleep-disordered Breathing in the Wisconsin Sleep Cohort Study,” American Journal of Respiratory and Critical Care Medicine 167, no. 9 (2003): 1181–1185.

[59] C. Antonaglia, G. M. Citton, M. Siciliano, B. Ruaro, F. Salton, and M. Confalonieri, “Obstructive Sleep Apnea Syndrome in Women: Gender in Sleep respiratory Medicine Is a First Step towards Personalized Medicine,” Sleep & Breathing = Schlaf & Atmung 29, no. 4 (2025): 250.

[60] E. I. Schwarz and S. Schiza, “Sex Differences in Sleep and Sleep-disordered Breathing,” Current Opinion in Pulmonary Medicine 30, no. 6 (2024): 593–599.

[61] J. Theorell-Haglöw, C. B. Miller, D. J. Bartlett, B. J. Yee, H. D. Openshaw, and R. R. Grunstein, “Gender Differences in Obstructive Sleep Apnoea, Insomnia and Restless Legs Syndrome in Adults – What Do We Know? A Clinical Update,” Sleep Medicine Reviews 38 (2018): 28–38.

[62] G. L. Dunietz, R. D. Chervin, R. Tauman, S. Shaklai, and A. Sankari, “OSA in Women: Associations with Reproductive Aging and Screening Challenges,” Chest 169, no. 3 (2026): 803–812, Published online August 28, 2025:S0012-3692(25)05125-6.

[63] M. R. Bonsignore, E. Mazzuca, P. Baiamonte, B. Bouckaert, W. Verbeke, and D. A. Pevernagie, “REM Sleep Obstructive Sleep Apnoea,” European Respiratory Review 33, no. 171 (2024): 230166.

[64] D. L. Mann, E. Staykov, T. Georgeson, et al., “Flow Limitation Is Associated With Excessive Daytime Sleepiness in Individuals Without Moderate or Severe Obstructive Sleep Apnea,” Annals of the American Thoracic Society 21, no. 8 (2024): 1186–1193.

[65] E. Fontanilles Arbones, N. Salord Oleo, M. Gasa Galmes, et al., “Phenotypes of Obstructive Sleep Apnea in Women: A Real-life Cohort Study,” Sleep Medicine 121 (2024): 295–302.

[66] E. S. Sigurðardóttir, T. Gislason, B. Benediktsdottir, et al., “Female Sex Hormones and Symptoms of Obstructive Sleep Apnea in European Women of a Population-based Cohort,” PLoS ONE 17, no. 6 (2022): e0269569.

[67] E. Shahar, S. Redline, T. Young, et al., “Hormone Replacement Therapy and Sleep-disordered Breathing,” American Journal of Respiratory and Critical Care Medicine 167, no. 9 (2003): 1186–1192.

[68] A. G. Mirer, P. E. Peppard, M. Palta, R. M. Benca, A. Rasmuson, and T. Young, “Menopausal Hormone Therapy and Sleep-disordered Breathing: Evidence for a Healthy User Bias,” Annals of Epidemiology 25, no. 10 (2015): 779–784.e1.

[69] F. L. Facco, D. W. Ouyang, P. C. Zee, and W. A. Grobman, “Sleep Disordered Breathing in a High-risk Cohort Prevalence and Severity Across Pregnancy,” American Journal of Perinatology 31, no. 10 (2014): 899–904.

[70] G. W. Pien, A. I. Pack, N. Jackson, G. Maislin, G. A. Macones, and R. J. Schwab, “Risk Factors for Sleep-disordered Breathing in Pregnancy,” Thorax 69, no. 4 (2014): 371–377.

[71] S. Farid, M. Giunio-Zorkin, D. J. Schust, and R. Cortese, “Obstructive Sleep Apnea in Pregnancy: A Review of the Literature From the Obstetrics Practitioner's View and a Proposed Clinical Approach,” European Journal of Obstetrics, Gynecology, and Reproductive Biology 300 (2024): 29–34.

[72] M. Manconi, L. C. van der Gaag, F. Mangili, et al., “Sleep and Sleep Disorders During Pregnancy and Postpartum: The Life-ON Study,” Sleep Medicine 113 (2024): 41–48.

[73] N. Esmaeili, L. Gell, T. Imler, et al., “The Relationship Between Obesity and Obstructive Sleep Apnea in Four Community-based Cohorts: An Individual Participant Data Meta-analysis of 12,860 Adults,” EClinicalMedicine 83 (2025): 103221.

[74] P. J. Hartfield, J. Janczy, A. Sharma, et al., “Anatomical Determinants of Upper Airway Collapsibility in Obstructive Sleep Apnea: A Systematic Review and Meta-analysis,” Sleep Medicine Reviews 68 (2023): 101741.

[75] R. J. Schwab, M. Pasirstein, R. Pierson, et al., “Identification of Upper Airway Anatomic Risk Factors for Obstructive Sleep Apnea With Volumetric Magnetic Resonance Imaging,” American Journal of Respiratory and Critical Care Medicine 168, no. 5 (2003): 522–530.

[76] A. M. Kim, B. T. Keenan, N. Jackson, et al., “Tongue Fat and Its Relationship to Obstructive Sleep Apnea,” Sleep 37, no. 10 (2014): 1639–1648.

[77] S. Isono, “Obesity and Obstructive Sleep Apnoea: Mechanisms for Increased Collapsibility of the Passive Pharyngeal Airway,” Respirology 17, no. 1 (2012): 32–42.

[78] L. Messineo, J. P. Bakker, J. Cronin, J. Yee, and D. P. White, “Obstructive Sleep Apnea and Obesity: A Review of Epidemiology, Pathophysiology and the Effect of Weight-loss Treatments,” Sleep Medicine Reviews 78 (2024): 101996.

[79] M. Polotsky, A. S. Elsayed-Ahmed, L. Pichard, et al., “Effects of Leptin and Obesity on the Upper Airway Function,” Journal of Applied Physiology (1985) 112, no. 10 (2012): 1637–1643.

[80] P. E. Peppard, “Longitudinal Study of Moderate Weight Change and Sleep-Disordered Breathing,” Jama 284, no. 23 (2000): 3015.

[81] S. T. Kuna, D. M. Reboussin, E. S. Strotmeyer, et al., “Effects of Weight Loss on Obstructive Sleep Apnea Severity. Ten-Year Results of the Sleep AHEAD Study,” American Journal of Respiratory and Critical Care Medicine 203, no. 2 (2021): 221–229.

[82] K. Sutherland, G. Smith, A. B. Lowth, et al., “The Effect of Surgical Weight Loss on Upper Airway Fat in Obstructive Sleep Apnoea,” Sleep & Breathing = Schlaf & Atmung 27, no. 4 (2023): 1333–1341.

[83] S. H. Wang, B. T. Keenan, A. Wiemken, et al., “Effect of Weight Loss on Upper Airway Anatomy and the Apnea-Hypopnea Index. The Importance of Tongue Fat,” American Journal of Respiratory and Critical Care Medicine 201, no. 6 (2020): 718–727.

[84] A. Malhotra, R. R. Grunstein, I. Fietze, et al., “Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity,” New England Journal of Medicine 391, no. 13 (2024): 1193–1205.

[85] Y. Chu and A. Zinchuk, “The Present and Future of the Clinical Use of Physiological Traits for the Treatment of Patients With OSA: A Narrative Review,” JCM 13, no. 6 (2024): 1636.

[86] A. Malhotra, A. Lucia Fuentes, and B. A. Edwards, “Is Obstructive Sleep Apnea in People without Obesity a Unique Disease?,” Archivos De Bronconeumologia 61, no. 7 (2025): 393–394.

[87] A. I. Acevedo-Fontanez and S. R. Patel, “Racial Disparities in Obstructive Sleep Apnea Care in the United States,” Sleep 48, no. 6 (2025): zsaf078.

[88] S. Agarwal, P. Monsod, Y. S. Cho, et al., “Racial Disparity in Obstructive Sleep Apnea Care and Its Impact on Cardiovascular Health,” Current Sleep Medicine Reports 10, no. 4 (2024): 414–418.

[89] S. Gueye-Ndiaye, A. A. Williamson, and S. Redline, “Disparities in Sleep-Disordered Breathing: Upstream Risk Factors, Mechanisms, and Implications,” Clinics in Chest Medicine 44, no. 3 (2023): 585–603.

[90] A. M. May, S. R. Patel, M. Yamauchi, et al., “Moving Toward Equitable Care for Sleep Apnea in the United States: Positive Airway Pressure Adherence Thresholds: An Official American Thoracic Society Policy Statement,” American Journal of Respiratory and Critical Care Medicine 207, no. 3 (2023): 244–254.

[91] V. H. C. Wang, Y. Li, D. T. Kent, et al., “Racial and Ethnic Differences in the Receipt of Continuous Positive Airway Pressure Treatment for Obstructive Sleep Apnea,” Sleep Medicine 124 (2024): 42–49.

[92] Y. Leng, C. Cavaillès, C. Peltz, S. E. O'Bryant, S. Redline, and K. Yaffe, “Racial and Ethnic and Sex Differences in at-Home Estimates of Obstructive Sleep Apnea Parameters Among Diverse Adults,” Annals of the American Thoracic Society 22, no. 9 (2025): 1401–1408.

[93] C. M. Ellender, W. R. Ruehland, B. Duce, et al., “Australasian Sleep Association 2024 Guidelines for Sleep Studies in Adults,” Sleep 47, no. 10 (2024): zsae107.

[94] O. de Palombini L, M. Assis, L. F. Drager, et al., “2024 Position Statement on the Use of Different Diagnostic Methods for Sleep Disorders in Adults—Brazilian Sleep Association,” Sleep Science 17, no. 4 (2024): e476–e492.

[95] J. Ko, J. H. Lim, D. B. Kim, et al., “Association Between Alcohol Use Disorder and Risk of Obstructive Sleep Apnea,” Journal of Sleep Research 33, no. 4 (2024): e14128.

[96] S. Mauries, B. Rolland, J. Frija-Masson, et al., “Sleep Apnea and Substance Use: A Meta-analysis,” Sleep Medicine Reviews 85 (2026): 102228.

[97] Y. S. Jang, N. Nerobkova, K. Hurh, E. C. Park, and J. Shin, “Association Between Smoking and Obstructive Sleep Apnea Based on the STOP-Bang Index,” Scientific Reports 13, no. 1 (2023): 9085.

[98] A. Pisano, C. Zoccali, D. Bolignano, G. D'Arrigo, and F. Mallamaci, “Sleep Apnoea Syndrome Prevalence in Chronic Kidney Disease and End-stage Kidney Disease Patients: A Systematic Review and Meta-analysis,” Clinical Kidney Journal 17, no. 1 (2024): sfad179.

[99] J. Jamwal, S. M. Qadri, F. Siraj, and S. Shah, “Prevalence of Obstructive Sleep Apnea in Patients With Chronic Kidney Disease: A Hospital-based Study,” Sleep & Breathing = Schlaf & Atmung 27, no. 5 (2023): 1703–1708.

[100] F. Zhang, X. Huang, H. Wang, et al., “Prevalence of Obstructive Sleep Apnea in Whole Spectrum Chronic Kidney Disease Patients: A Systematic Review and Meta-analysis,” Sleep Medicine 119 (2024): 526–534.

[101] L. H. Lancaster, W. R. Mason, J. A. Parnell, et al., “Obstructive Sleep Apnea Is Common in Idiopathic Pulmonary Fibrosis,” Chest 136, no. 3 (2009): 772–778.

[102] J. H. Lee, J. H. Jang, J. H. Park, et al., “Prevalence and Clinical Impacts of Obstructive Sleep Apnea in Patients With Idiopathic Pulmonary Fibrosis: A Single-center, Retrospective Study. Xu L, Ed,” PLoS ONE 18, no. 9 (2023): e0291195.

[103] F. F. Karuga, P. Kaczmarski, B. Szmyd, P. Białasiewicz, M. Sochal, and A. Gabryelska, “The Association Between Idiopathic Pulmonary Fibrosis and Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis,” Journal of Clinical Medicine 11, no. 17 (2022): 5008.

[104] C. Gouveia Cardoso, C. Valente, M. Serino, et al., “Obstructive Sleep Apnea in Patients With Fibrotic Interstitial Lung Disease (non-idiopathic pulmonary fibrosis): What Should be Offered?,” Jornal Brasileiro de Pneumologia 50, no. 5 (2024): e20240058, Published online November 12, 2024: e20240058.

[105] I. Jullian-Desayes, W. Trzepizur, J. Boursier, et al., “Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease and NAFLD: An Individual Participant Data Meta-analysis,” Sleep Medicine 77 (2021): 357–364.

[106] G. Musso, M. Cassader, C. Olivetti, F. Rosina, G. Carbone, and R. Gambino, “Association of Obstructive Sleep Apnoea With the Presence and Severity of Non-alcoholic Fatty Liver Disease. A Systematic Review and Meta-analysis,” Obesity Reviews 14, no. 5 (2013): 417–431.

[107] F. Tacke, P. Horn, V. Wai-Sun Wong, et al., “EASL–EASD–EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD),” Journal of Hepatology 81, no. 3 (2024): 492–542.

[108] K. A. Dudley and S. R. Patel, “Disparities and Genetic Risk Factors in Obstructive Sleep Apnea,” Sleep Medicine 18 (2016): 96–102.

[109] R. W. W. Lee, S. Vasudavan, D. S. Hui, et al., “Differences in Craniofacial Structures and Obesity in Caucasian and Chinese Patients With Obstructive Sleep Apnea,” Sleep 33, no. 8 (2010): 1075–1080.

[110] A. I. Campos, N. Ingold, Y. Huang, et al., “Discovery of Genomic Loci Associated With Sleep Apnea Risk Through Multi-trait GWAS Analysis With Snoring,” Sleep 46, no. 3 (2023): zsac308.

[111] H. Liu, D. Li, C. Gao, et al., “A Systematic Review and Meta-Analysis of 35,409 Patients Undergoing PCI versus CABG for Unprotected Left Main Coronary Artery Diseases,” Reviews in Cardiovascular Medicine 25, no. 8 (2024): 282.

[112] B. A. Edwards, S. A. Landry, L. D. J. Thomson, and S. A. Joosten, “Sleep Apnea Endotypes and Their Implications for Clinical Practise,” Sleep Medicine 126 (2025): 260–266.

[113] J. R. Raphelson, A. L. Fuentes, B. Holloway, and A. Malhotra, “Obstructive Sleep Apnea Endophenotypes,” Sleep Science 18, no. 1 (2025): e109–e113.

[114] T. Tolbert, I. Ayappa, and D. Rapoport, “OSA Pathophysiology: A Contemporary Update,” Australian Dental Journal 69, no. S1 (2024): S68–S83.

[115] L. W. Hang, Y. C. Tsai, E. Finnsson, J. S. Ágústsson, S. A. Sands, and W. J. Cheng, “Sex-specific Age-related Worsening of Pathological Endotypic Traits in Patients With Obstructive Sleep Apnea,” Sleep 48, no. 1 (2025): zsae185.

[116] C. Strassberger, J. Hedner, S. A. Sands, et al., “Night-to-Night Variability of Polysomnography-Derived Physiologic Endotypic Traits in Patients with Moderate to Severe OSA,” Chest 163, no. 5 (2023): 1266–1278.

[117] D. J. Hynes, D. L. Mann, S. A. Landry, S. A. Joosten, B. A. Edwards, and G. S. Hamilton, “Night-to-night Variability in Obstructive Sleep Apnea Severity, the Physiological Endotypes, and the Frequency of Flow Limitation,” Sleep 48, no. 4 (2025): zsae295.

[118] A. Parekh, “Hypoxic Burden—definitions, Pathophysiological Concepts, Methods of Evaluation, and Clinical Relevance,” Current Opinion in Pulmonary Medicine 30, no. 6 (2024): 600–606.

[119] M. Blanchard, T. Imler, W. H. Hu, et al., “Heart Rate Response and Cardiovascular Risk During Obstructive Sleep Apnoea: An Easy Biomarker Derived From Pulse Oximetry,” European Respiratory Journal 65, no. 5 (2025): 2401883.

[120] M. Hajipour, W. H. Hu, N. Esmaeili, et al., “Sleep Apnea Physiological Burdens and Markers of White Matter Injury: The Multi-Ethnic Study of Atherosclerosis,” Journal of Clinical Sleep Medicine 21, no. 3 (2025): 457–466.

[121] D. E. Berisha, B. Rizvi, M. G. Chappel-Farley, et al., “Association of Hypoxemia due to Obstructive Sleep Apnea with White Matter Hyperintensities and Temporal Lobe Changes in Older Adults,” Neurology 104, no. 11 (2025): e213639.

[122] I. Moussa, L. Ben Hmida, H. Mrassi, I. Sahnoun, and L. Douik El Gharbi, “Impact of Mean Apnea-hypopnea Duration on Disease Severity in Obstructive Sleep Apnea: A Retrospective Study,” Respiratory Medicine 251 (2026): 108581.

[123] M. Orban, C. J. Bruce, G. S. Pressman, et al., “Dynamic Changes of Left Ventricular Performance and Left Atrial Volume Induced by the Mueller Maneuver in Healthy Young Adults and Implications for Obstructive Sleep Apnea, Atrial Fibrillation, and Heart Failure,” The American Journal of Cardiology 102, no. 11 (2008): 1557–1561.

[124] G. S. Pressman, M. Orban, P. Leinveber, et al., “Effects of the Mueller Maneuver on Functional Mitral Regurgitation and Implications for Obstructive Sleep Apnea,” American Journal of Cardiology 115, no. 11 (2015): 1563–1567.

[125] C. Schlatzer, E. I. Schwarz, N. A. Sievi, et al., “Intrathoracic Pressure Swings Induced by Simulated Obstructive Sleep Apnoea Promote Arrhythmias in Paroxysmal Atrial Fibrillation,” Europace 18, no. 1 (2016): 64–70.

[126] J. A. Dempsey, S. C. Veasey, B. J. Morgan, and C. P. O'Donnell, “Pathophysiology of Sleep Apnea,” Physiological Reviews 90, no. 1 (2010): 47–112.

[127] A. S. Jordan, D. G. McSharry, and A. Malhotra, “Adult Obstructive Sleep Apnoea,” Lancet 383, no. 9918 (2014): 736–747.

[128] B. Nokes, A. Schueler, C. Darquenne, et al., “The Impact of Obesity on Upper Airway Anatomy as Assessed by Magnetic Resonance Imaging and Obstructive Sleep Apnea Endotypic Traits,” Frontiers in Physiology 16 (2025): 1648767.

[129] L. Xu, B. T. Keenan, A. S. Wiemken, et al., “The Relationship Between Upper Airway Anatomy and Obesity in Patients With Obstructive Sleep Apnea,” Annals of the American Thoracic Society 22, no. 11 (2025): 1749–1763.

[130] E. Baker, M. Chanamolu, C. Nieri, S. F. White, J. Brandt, and M. B. Gillespie, “The Effect of Tongue Volume and Adipose Content on Obstructive Sleep Apnea: Meta-analysis & Systematic Review,” OTO Open 9, no. 2 (2025): e70067.

[131] T. Harkins, A. Tangutur, B. T. Keenan, et al., “Pharyngeal Manometry and Upper Airway Collapse during Drug-Induced Sleep Endoscopy,” JAMA Otolaryngology – Head & Neck Surgery 150, no. 10 (2024): 869.

[132] E. Schoustra, M. Leentjens, J. P. van Maanen, M. J. van Looij, N. de Vries, and M. J. L. Ravesloot, “Predicting Complete Concentric Collapse at the Palatal Level During Drug-induced Sleep Endoscopy: An Analysis of 1761 Cases,” Sleep & Breathing = Schlaf & Atmung 29, no. 1 (2024): 22.

[133] A. Sharma, J. Noel, and B. T. Woodson, “Home Sleep Study Nasal Airflow Patterns and Epiglottic Collapse During Drug Induced Sleep Endoscopy,” Sleep & Breathing = Schlaf & Atmung 29, no. 2 (2025): 142.

[134] S. Jin, M. Kim, H. J. Kim, et al., “Evaluation of Oropharyngeal Structure and DISE Findings for Successful Soft Palatal Webbing Flap Pharyngoplasty,” Journal of Craniofacial Surgery 36, no. 3 (2025): 897–901.

[135] A. Maniaci, M. Lentini, J. R. Lechien, et al., “Head-of-bed Elevation Outcomes on Apnea Severity Nasal Resistance in Obstructive Sleep Apnea: A Multicenter Observational Study,” Sleep & Breathing = Schlaf & Atmung 29, no. 6 (2025): 359.

[136] M. Mladoňová, K. Fedorová, O. Jor, et al., “The Role of Positional Changes in Optimizing OSA Treatment: Evidence From DISE,” European Archives of Oto-Rhino-Laryngology 282, no. 5 (2025): 2709–2717.

[137] D. Mitsikas, B. Jakob, V. Janjic, C. Hasler, and S. Tschopp, “Interrater Reliability of Different Scoring Systems for Drug-induced Sleep Endoscopy,” Sleep & Breathing = Schlaf & Atmung 29, no. 1 (2025): 27.

[138] D. Kumar, B. T. Woodson, and G. J. M. Garcia, “Phenotypes of Velopharyngeal Tube Law in Obstructive Sleep Apnea,” Otolaryngology – Head & Neck Surgery 172, no. 1 (2025): 336–345.

[139] T. Y. Wang, P. Huyett, H. Yang, et al., “Lateral Epiglottic Collapse in Obstructive Sleep Apnea Is Associated With Laterally Directed Pharyngeal Collapse,” Journal of Clinical Sleep Medicine 21, no. 4 (2025): 649–654.

[140] S. Op de Beeck, D. Vena, E. Van de Perck, et al., “Site of Collapse During Drug-induced Sleep Endoscopy Is Associated With Polysomnographic Endotypic Traits: An Observational Study,” Annals of the American Thoracic Society 22, no. 10 (2025): 1567–1578.

[141] R. J. Schwab, T. C. Lin, A. Wiemken, R. C. Dedhia, F. W. Wehrli, and B. T. Keenan, “State-Dependent Biomechanical Behavior of Oropharyngeal Structures in Apneic and Control Subjects: A Proof-of-Concept Study,” Annals of the American Thoracic Society 21, no. 6 (2024): 949–960.

[142] M. A. Degerli, O. Hildebrandt, U. Koehler, et al., “[Critical Closing Pressure (Pcrit) and Negative (Subatmospheric) Expiratory Pressure (NEP) for Diagnosis of Pharyngeal Collapsibility in Patients With Obstructive Sleep Apnea (OSA)],” Pneumologie 79, no. 6 (2025): 415–420.

[143] X. Wang, J. Zhang, J. Zou, et al., “Polysomnographic Endotypes of Successful Multilevel Upper Airway Surgery for Obstructive Sleep Apnea,” Sleep 48, no. 5 (2025): zsaf012.

[144] E. Tukanov, M. Dieltjens, A. E. Verbruggen, et al., “Effect of Mandibular Advancement Device Treatment on the Site-Specific Degree of Upper Airway Collapse during Drug-Induced Sleep Endoscopy,” JCM 14, no. 22 (2025): 8142.

[145] W. A. Alrubasy, M. T. Abuawwad, M. J. J. Taha, et al., “Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea in Adults: An Updated Systematic Review and Meta-analysis,” Respiratory Medicine 234 (2024): 107826.

[146] S. A. Sands, J. Collet, L. K. Gell, et al., “Combination Pharmacological Therapy Targeting Multiple Mechanisms of Sleep Apnoea: A Randomised Controlled Cross-Over Trial,” Thorax 79, no. 3 (2024): 259–268.

[147] P. K. Schweitzer, L. Taranto-Montemurro, J. M. Ojile, et al., “The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial,” American Journal of Respiratory and Critical Care Medicine 208, no. 12 (2023): 1316–1327.

[148] R. Lv, X. Liu, Y. Zhang, et al., “Pathophysiological Mechanisms and Therapeutic Approaches in Obstructive Sleep Apnea Syndrome,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 218.

[149] J. A. Patel, B. J. Ray, C. Fernandez-Salvador, C. Gouveia, S. Zaghi, and M. Camacho, “Neuromuscular Function of the Soft Palate and Uvula in Snoring and Obstructive Sleep Apnea: A Systematic Review,” American Journal of Otolaryngology 39, no. 3 (2018): 327–337.

[150] L. Messineo, M. Preuss, A. Azarbarzin, et al., “Effects of the Combination of Pimavanserin and Atomoxetine on OSA Severity,” Chest 168, no. 1 (2025): 223–235.

[151] L. Taranto-Montemurro, L. Messineo, A. Azarbarzin, et al., “Effects of the Combination of Atomoxetine and Oxybutynin on OSA Endotypic Traits,” Chest 157, no. 6 (2020): 1626–1636.

[152] C. J. Beatty, S. A. Landry, D. L. Mann, et al., “The Impact of Exercise Training on the Obstructive Sleep Apnea Endotypes,” Sleep Medicine 139 (2026): 108740.

[153] Y. Li, A. R. Schwartz, D. Zealear, et al., “Ansa Cervicalis Stimulation Effects on Upper Airway Patency: A Structure-based Analysis,” European Respiratory Journal 65, no. 1 (2025): 2400901.

[154] H. Er Ulubaba, N. Dağ, S. Demiröz Taşolar, R. Çiftçi, and H. Ermiş, “Quantitative Assessment of Extrinsic Tongue Muscle Stiffness in Obstructive Sleep Apnea Using Shear Wave Elastography,” Diagnostics 16, no. 1 (2025): 87.

[155] Q. Xiao and A. Bates, “Quantifying Neuromuscular and Pressure Force Dynamics in Obstructive Sleep Apnea: A Novel Computational Fluid Dynamics Approach Using Airway Wall Acceleration,” Journal of Biomechanical Engineering 147, no. 10 (2025): 101009.

[156] C. Li, H. Fan, Y. Duan, et al., “Effects of Dexmedetomidine and Propofol on the Key Endotypes of OSA: A Randomized, Single-blind, Placebo-controlled, Crossover Trial,” Sleep Medicine 129 (2025): 132–139.

[157] C. Antonaglia, G. M. Citton, S. Soave, et al., “Deciphering Loop Gain Complexity: A Primer for Understanding a Pathophysiological Trait of Obstructive Sleep Apnea Patients,” Respiratory Medicine 234 (2024): 107820.

[158] W. Randerath, L. Grote, K. Stenlöf, et al., “Sultiame Once per Day in Obstructive Sleep Apnoea (FLOW): A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-finding, Phase 2 Trial,” Lancet 406, no. 10514 (2025): 1983–1992.

[159] S. Puri, M. El-Chami, D. Shaheen, et al., “Variations in Loop Gain and Arousal Threshold During NREM Sleep Are Affected by Time of Day Over a 24-hour Period in Participants With Obstructive Sleep Apnea,” Journal of Applied Physiology (1985) 129, no. 4 (2020): 800–809.

[160] B. A. Edwards, L. D. J. Thomson, D. Vena, et al., “Combined Supplemental Oxygen and Mandibular Advancement Device Therapy for Obstructive Sleep Apnoea: A Randomised Controlled Trial,” European Respiratory Journal 67, no. 1 (2026): 2501320.

[161] L. D. J. Thomson, S. A. Landry, K. Maddison, et al., “The Impact of Acetazolamide and Dronabinol on the Physiological Endotypes Responsible for Obstructive Sleep Apnea,” Sleep Medicine 132 (2025): 106542.

[162] L. D. J. Thomson, S. A. Landry, A. Arellano, et al., “The Effect of M-current Activation on Controller Gain and Obstructive Sleep Apnoea Severity: A Randomised Controlled Trial Using flupirtine,” The Journal of Physiology 603, no. 10 (2025): 3245–3260.

[163] U. L. Opsahl, M. Berge, S. Lehmann, B. Bjorvatn, and A. Johansson, “Prediction of Non-responders to Oral Appliance Treatment of Obstructive Sleep Apnea: A Pilot Study,” Sleep & Breathing = Schlaf & Atmung 29, no. 2 (2025): 159.

[164] L. Messineo, S. A. Sands, and G. Labarca, “Hypnotics on Obstructive Sleep Apnea Severity and Endotypes: A Systematic Review and Meta-Analysis,” American Journal of Respiratory and Critical Care Medicine 210, no. 12 (2024): 1461–1474.

[165] P. Pisalnoradej, W. Banhiran, and N. Kasemsuk, “The Effect of Zolpidem on CPAP Acclimatization in Patients With OSA: A Crossover, Randomized, Double-blinded, Placebo-controlled Trial,” Journal of Clinical Sleep Medicine 21, no. 11 (2025): 1831–1837.

[166] S. A. Joosten, S. A. Landry, A. M. Wong, et al., “Assessing the Physiologic Endotypes Responsible for REM- and NREM-Based OSA,” Chest 159, no. 5 (2021): 1998–2007.

[167] L. Messineo, D. J. Eckert, L. Taranto-Montemurro, et al., “Ventilatory Drive Withdrawal Rather than Reduced Genioglossus Compensation as a Mechanism of Obstructive Sleep Apnea in REM Sleep,” American Journal of Respiratory and Critical Care Medicine 205, no. 2 (2022): 219–232.

[168] S. Wellekens, E. Vanderhelst, S. Verbanck, and S. De Weerdt, “REM-predominant Obstructive Sleep Apnea: An Unmet Clinical Need,” Sleep & Breathing = Schlaf & Atmung 29, no. 1 (2025): 97.

[169] Y. Shi, X. Gao, J. Liao, Y. Li, and D. Han, “Exploring the Arousal Intensity in Patients With Obstructive Sleep Apnea: Based on Odds Ratio Product,” Nature and Science of Sleep 17 (2025): 2065–2078.

[170] N. Banluesombatkul, E. Mignot, and T. Wilaiprasitporn, “Comprehensive Evaluation of Odds Ratio Product and Spectral Slope as Continuous Sleep Depth Measures: Advancing Sleep Staging and Clinical Applications,” Sleep 48, no. 10 (2025): zsaf130.

[171] A. V. Zinchuk, C. A. Kushida, A. Walker, et al., “Arousal Threshold Modifies the Effect of CPAP on Executive Function Among Individuals With Obstructive Sleep Apnoea,” European Respiratory Journal 65, no. 2 (2025): 2401183.

[172] B. Y. Sunwoo and A. Malhotra, “Mechanical Interactions between the Upper Airway and the Lungs That Affect the Propensity to Obstructive Sleep Apnea in Health and Chronic Lung Disease,” Sleep Medicine Clinics 19, no. 2 (2024): 211–218.

[173] J. Tong, L. Jugé, P. G. Burke, et al., “Respiratory-related Displacement of the Trachea in Obstructive Sleep Apnea,” Journal of Applied Physiology 127, no. 5 (2019): 1307–1316.

[174] J. Raphelson, A. Sanchez-Azofra, J. E. Orr, et al., “Obstructive Sleep Apnea Severity and Pathophysiological Traits in Overlap Syndrome: Insights From the SNOOzzzE Cohort,” Physiological Reports 13, no. 13 (2025): e70438.

[175] M. R. Wilson, R. Carroll, S. Kinder, et al., “Prospective Crossover Trial of Positional and CPAP Therapy for the Treatment of Mild-to-moderate Positional Obstructive Sleep Apnea,” Journal of Clinical Sleep Medicine 21, no. 2 (2025): 305–313.

[176] W. J. Cheng, E. Finnsson, J. S. Ágústsson, S. A. Sands, and L. W. Hang, “Endotypic Traits of Supine Position and Supine-predominant Obstructive Sleep Apnoea in Asian Patients,” European Respiratory Journal 63, no. 3 (2024): 2301660.

[177] A. Polecka, N. Olszewska, M. Pulido, and E. Olszewska, “Rostral Fluid Shifts and Other Mechanisms of Interaction Between Obstructive Sleep Apnea and Heart Failure – a Systematic Review,” Otolaryngologia Polska 78, no. 5 (2024): 10–17.

[178] C. Segsarnviriya, M. Prakassajjatham, N. Chirakalwasan, P. Hirunwiwatkul, B. Chaitusaney, and N. Charakorn, “The Use of Topical Nasal Steroids to Improve Continuous Positive Airway Pressure Compliance in Patients With Obstructive Sleep Apnea: An Updated Systematic Review and Meta-analysis of Randomized Control Trials,” Asian Pacific Journal of Allergy and Immunology 43, no. 2 (2025): 206–213.

[179] B. Lechat, D. P. Nguyen, K. Sansom, et al., “Obstructive Sleep Apnea Severity Varies by Season and Environmental Influences Such as Ambient Temperature,” Communications Medicine (London) 5, no. 1 (2025): 314.

[180] X. Wang, T. Zhou, W. Huang, et al., “Differences in Physiologic Endotypes between Nonpositional and Positional OSA: Results from the Shanghai Sleep Health Study Cohort,” Chest 166, no. 1 (2024): 212–225.

[181] N. Thanh Tung, Y. L. Lee, W. T. Liu, et al., “Impact of PM2.5, Relative Humidity, and Temperature on Sleep Quality: A Cross-sectional Study in Taipei,” Annals of Medicine 57, no. 1 (2025): 2448733.

[182] S. Lee, J. H. Park, J. Y. Kim, S. W. Park, H. B. Shin, and B. H. Kim, “Implementation of Head of Bed Elevation Using Adjustable Bed and Its Effects on Sleep: A Pilot Randomized Trial,” Alternative Therapies in Health and Medicine 31, no. 3 (2025): 122–128.

[183] N. Kurniansyah, S. J. Strausz, G. Chittoor, et al., “Polygenic Scores for Obstructive Sleep Apnoea Reveal Pathways Contributing to Cardiovascular Disease,” EBioMedicine 117 (2025): 105790.

[184] T. Sofer, N. Kurniansyah, M. Murray, et al., “Genome-wide Association Study of Obstructive Sleep Apnoea in the Million Veteran Program Uncovers Genetic Heterogeneity by Sex,” EBioMedicine 90 (2023): 104536.

[185] F. Cai, W. Hong, C. Xiong, et al., “Exploring the Genetic Link Between Obstructive Sleep Apnea and Obesity: A Bidirectional Mendelian Randomization Study,” Respiratory Medicine 252 (2026): 108609.

[186] N. Dong and H. Yue, “Advances in Immunology of Obstructive Sleep Apnea: Mechanistic Insights, Clinical Impact, and Therapeutic Perspectives,” Frontiers in immunology 16 (2025): 1654450.

[187] M. Wei, J. A. Teske, S. Mashaqi, and D. Combs, “Obstructive Sleep Apnea, the NLRP3 Inflammasome and the Potential Effects of Incretin Therapies,” Front Sleep 3 (2025): 1524593.

[188] Y. Zhao, Y. Jiang, Y. Wang, et al., “Novel Susceptibility Genes and Biomarkers for Obstructive Sleep Apnea: Insights From Genetic and Inflammatory Proteins,” Sleep 48, no. 2 (2025): zsae169.

[189] X. Sun, C. Wang, Y. He, K. Chen, and Y. Miao, “Effect of Inflammatory Cytokines and Plasma Metabolome on OSA: A Bidirectional Two- sample Mendelian Randomization Study and Mediation Analysis,” Frontiers in immunology 15 (2024): 1416870.

[190] Z. Wang, D. A. Wallace, B. W. Spitzer, et al., “Methylation Risk Score of C-reactive Protein Associates Sleep Health With Related Health Outcomes,” Communications Biology 8, no. 1 (2025): 821.

[191] Z. Wang and T. Sofer, “Recent Progress in Omics Studies of Sleep and Circadian Phenotypes,” Current Sleep Medicine Reports 11, no. 1 (2025): 17.

[192] E. Engal and A. Gileles-Hillel, “Epigenetic Alterations in Obstructive Sleep Apnea: A Pooled Analysis of DNA Methylation Profiles in Humans and Animal Models,” Clinical Epigenetics 17, no. 1 (2025): 194.

[193] X. Zhang and L. Ren, “Dynamic Genetic Regulation of CD4+ T Cells in Obstructive Sleep Apnea: Integrating Context-specific eQTL, Mendelian Randomization, Single-cell Sequencing, and Experimental Validation,” Frontiers in immunology 16 (2025): 1691347.

[194] P. Liu, X. Yang, and G. C. Li, “Transcriptomic and Polysomnographic Insights into Core Signaling Pathways in Obstructive Sleep Apnea. Jinhui L, Ed,” Mediators of Inflammation 2025, no. 1 (2025): 4579543.

[195] S. Turkiewicz, M. Sochal, M. Ditmer, et al., “Exploring Differences in Signaling Pathways of the Circadian Clock and Neuromodulators in Obstructive Sleep Apnea,” Scientific Reports 15, no. 1 (2025): 14661.

[196] J. Alcock, “Obstructive Sleep Apnea and the Gut Microbiota—mechanisms and Opportunities,” Current Opinion in Pulmonary Medicine 31, no. 6 (2025): 605–612.

[197] Y. Guo, S. Sun, Y. Wang, et al., “Microbial Dysbiosis in Obstructive Sleep Apnea: A Systematic Review and Meta-analysis,” Frontiers in Microbiology 16 (2025): 1572637.

[198] S. Wei, R. Shen, X. Lu, et al., “Integrative Multi-omics Investigation of Sleep Apnea: Gut Microbiome Metabolomics, Proteomics and Phenome-wide Association Study,” Nutrition & Metabolism (London) 22, no. 1 (2025): 57.

[199] L. F. Drager, J. C. Jun, and V. Y. Polotsky, “Metabolic Consequences of Intermittent Hypoxia: Relevance to Obstructive Sleep Apnea,” Best Practice & Research Clinical Endocrinology & Metabolism 24, no. 5 (2010): 843–851.

[200] D. Lacedonia, G. E. Carpagnano, E. Crisetti, et al., “Mitochondrial DNA Alteration in Obstructive Sleep Apnea,” Respiratory Research 16, no. 1 (2015): 47.

[201] P. G. Meliante, F. Zoccali, F. Cascone, et al., “Molecular Pathology, Oxidative Stress, and Biomarkers in Obstructive Sleep Apnea,” IJMS 24, no. 6 (2023): 5478.

[202] M. Badran, R. Cortese, A. Gileles-Hillel, and D. Gozal, “Mechanisms Underlying End-organ Injury in Sleep Apnea,” European Respiratory Journal 67, no. 4 (2026): 2502397, Published online January 29, 2026: 2502397.

[203] M. A. Martinez-Garcia, M. Sánchez-de-la-Torre, D. P. White, and A. Azarbarzin, “Hypoxic Burden in Obstructive Sleep Apnea: Present and Future,” Archivos de Bronconeumología 59, no. 1 (2023): 36–43.

[204] K. Carlos, G. F. do Prado, and C. H. Tengan, “The Role of Mitochondria in Obstructive Sleep Apnea: Implications for the Upper Airway Muscles,” International Journal of Molecular Sciences 26, no. 21 (2025): 10562.

[205] M. A. Reveyaz, C. Peyronnel, Q. Boëte, et al., “Oxidative and Inflammatory Mechanisms Induced by Intermittent Hypoxia Leading to Vascular Alterations in Rodents: A Systematic Review and Meta-Analysis,” Oxidative Medicine and Cellular Longevity 2026 (2026): 9967028.

[206] C. Arnaud, E. Billoir, A. F. De Melo Junior, S. A. Pereira, K. D. O'Halloran, and E. C. Monteiro, “Chronic Intermittent Hypoxia-induced Cardiovascular and Renal Dysfunction: From Adaptation to Maladaptation,” The Journal of Physiology 601, no. 24 (2023): 5553–5577.

[207] T. H. G. Phan, P. Paliogiannis, G. K. Nasrallah, et al., “Emerging Cellular and Molecular Determinants of Idiopathic Pulmonary Fibrosis,” Cellular and Molecular Life Sciences 78, no. 5 (2021): 2031–2057.

[208] T. Wynn, “Cellular and Molecular Mechanisms of Fibrosis,” The Journal of Pathology 214, no. 2 (2008): 199–210.

[209] Z. Wang and L. Y. Si, “Hypoxia-inducible Factor-1α and Vascular Endothelial Growth Factor in the Cardioprotective Effects of Intermittent Hypoxia in Rats,” Upsala Journal of Medical Sciences 118, no. 2 (2013): 65–74.

[210] M. Badran, C. Puech, and D. Gozal, “Prolonged Intermittent Hypoxia Accelerates Cardiovascular Aging and Mortality: Insights From a Murine Model of OSA,” npj Aging 11, no. 1 (2025): 92.

[211] S. Naushad, J. Gaucher, Z. Mezdari, et al., “Chronic Intermittent Hypoxia Triggers Cardiac Fibrosis: Role of Epididymal White Adipose Tissue Senescent Remodeling?,” Acta Physiologica 240, no. 11 (2024): e14231.

[212] J. Kudo, H. Hirono, and S. Ohkoshi, “Low-frequency, Mild-gradient Chronic Intermittent Hypoxia Still Induces Liver Fibrogenesis in Mice on a High-fat Diet,” Biochemical and Biophysical Research Communications 761 (2025): 151744.

[213] Y. L. Chen, Y. C. Chen, H. T. Wang, et al., “The Impact of Intermittent Hypoxemia on Left Atrial Remodeling in Patients With Obstructive Sleep Apnea Syndrome,” Life 12, no. 2 (2022): 148.

[214] D. Linz, M. Hohl, A. Nickel, et al., “Effect of Renal Denervation on Neurohumoral Activation Triggering Atrial Fibrillation in Obstructive Sleep Apnea,” Hypertension 62, no. 4 (2013): 767–774.

[215] S. E. Schiza, I. Bouloukaki, M. Bolaki, and K. M. Antoniou, “Obstructive Sleep Apnea in Pulmonary Fibrosis,” Current Opinion in Pulmonary Medicine 26, no. 5 (2020): 443–448.

[216] C. A. Steiner, I. M. Cartwright, C. T. Taylor, and S. P. Colgan, “Hypoxia-inducible Factor as a Bridge Between Healthy Barrier Function, Wound Healing, and Fibrosis,” American Journal of Physiology-Cell Physiology 323, no. 3 (2022): C866–C878.

[217] S. Zhang, Y. Zhao, Z. Dong, et al., “HIF-1α Mediates Hypertension and Vascular Remodeling in Sleep Apnea via Hippo-YAP Pathway Activation,” Molecular Medicine 30, no. 1 (2024): 281.

[218] S. Jiang, X. Xing, M. Hong, X. Zhang, F. Xu, and G. H. Zhang, “Hsa_circ_0081065 exacerbates IH-induced EndMT via Regulating miR-665/HIF-1α Signal Axis and HIF-1α Nuclear Translocation,” Scientific Reports 14, no. 1 (2024): 904.

[219] Z. Maakoul, C. H. Yegen, D. Marchant, et al., “Interruption of Intermittent Hypoxia Attenuates the Severity of Pulmonary Fibrosis in Male Mice,” Physiological Reports 13, no. 10 (2025): e70335.

[220] J. Gaucher, E. Montellier, G. Vial, et al., “Long-term Intermittent Hypoxia in Mice Induces Inflammatory Pathways Implicated in Sleep Apnea and Steatohepatitis in Humans,” Iscience 27, no. 2 (2024): 108837.

[221] D. Lu and K. Wang, “The Relationship Between Obstructive Sleep Apnea and Atrial Remodeling, Fibrosis and Inflammation,” PLoS ONE 20, no. 8 (2025): e0328540.

[222] R. Wu, N. Chen, J. Li, D. Liu, F. Wang, and Q. Chen, “β-Sitosterol Attenuates Obstructive Sleep Apnea-related Myocardial Injury via MALAT1-mediated HIF-1α Regulation,” Frontiers in pharmacology 16 (2025): 1692758.

[223] R. Cetin-Atalay, A. Y. Meliton, Y. Tian, et al., “Sustained Hypoxia but Not Intermittent Hypoxia Induces HIF-1α Transcriptional Response in human Aortic Endothelial Cells,” Molecular Omics 21, no. 1 (2024): 19–31.

[224] T. R. Kıran, Ö. Otlu, M. Erdem, A. A. Geçkil, N. K. Berber, and E. İn, “The Effects of Disease Severity and Comorbidity on Oxidative Stress Biomarkers in Obstructive Sleep Apnea,” Sleep & Breathing = Schlaf & Atmung 28, no. 1 (2024): 151–163.

[225] S. Lavalle, E. Masiello, G. Iannella, et al., “Unraveling the Complexities of Oxidative Stress and Inflammation Biomarkers in Obstructive Sleep Apnea Syndrome: A Comprehensive Review,” Life 14, no. 4 (2024): 425.

[226] A. Marinelli, A. Portacci, A. Bikov, et al., “Role of Free Radicals in the Pathophysiology of OSA: A Narrative Review of a Double-Edged Sword,” JCM 14, no. 13 (2025): 4752.

[227] M. Ueyama, S. Koike, H. Kimura, and Y. Ogasawara, “Continual Hyperoxidation of Erythrocytic Peroxiredoxin 2 in Obstructive Sleep Apnoea: A Possible Biomarker of Oxidative Stress,” ERJ Open Research 11, no. 5 (2025): 00378–02025.

[228] S. S. Li, X. D. Tian, J. K. Song, C. Z. Wu, W. L. Wang, and Z. Tang, “Advanced Oxidation Protein Products in Obstructive Sleep Apnea Hypopnea Syndrome-A Systematic Review and Meta-Analysis,” Journal of Oral Rehabilitation 52, no. 10 (2025): 1591–1600.

[229] P. Mastino, D. Rosati, G. de Soccio, et al., “Oxidative Stress in Obstructive Sleep Apnea Syndrome: Putative Pathways to Hearing System Impairment,” Antioxidants (Basel) 12, no. 7 (2023): 1430.

[230] J. Zhang and S. Veasey, “Making Sense of Oxidative Stress in Obstructive Sleep Apnea: Mediator or Distracter?,” Frontiers in Neurology 3 (2012): 179.

[231] H. J. Eisele, P. Markart, and R. Schulz, “Obstructive Sleep Apnea, Oxidative Stress, and Cardiovascular Disease: Evidence From Human Studies,” Oxidative Medicine and Cellular Longevity 2015 (2015): 608438.

[232] M. F. McCarty, J. DiNicolantonio, and J. O'Keefe, “NADPH Oxidase, Uncoupled Endothelial Nitric Oxide Synthase, and NF-KappaB Are Key Mediators of the Pathogenic Impact of Obstructive Sleep Apnea – Therapeutic Implications,” Journal of Integrative Cardiology 2, no. 5 (2016): 1000177.

[233] R. Dumitrascu, J. Heitmann, W. Seeger, N. Weissmann, and R. Schulz, “Obstructive Sleep Apnea, Oxidative Stress and Cardiovascular Disease: Lessons From Animal Studies,” Oxidative Medicine and Cellular Longevity 2013 (2013): 234631.

[234] Q. Chen, D. Jiang, J. He, and M. Sun, “Hydrogen Rescues Vascular Endothelial Cells in Obstructive Sleep Apnea-hypopnea Syndrome by Modulating Nitric Oxide,” Journal of thoracic disease 17, no. 11 (2025): 9598–9609.

[235] K. Zhang, D. Ma, Y. Wu, and Z. Xu, “Impact of Chronic Intermittent Hypoxia on Cognitive Function and Hippocampal Neurons in Mice: A Study of Inflammatory and Oxidative Stress Pathways,” Nature and Science of Sleep 16 (2024): 2029–2043.

[236] A. Ninić, B. Rajkov, J. Kotur-Stevuljević, et al., “Association between Redox and Inflammatory Biomarkers With the Presence and Severity of Obstructive Sleep Apnea,” Medicina (Kaunas) 61, no. 9 (2025): 1557.

[237] Z. Zhang and J. Guo, “Deciphering Oxidative Stress in Cardiovascular Disease Progression: A Blueprint for Mechanistic Understanding and Therapeutic Innovation,” Antioxidants 14, no. 1 (2024): 38.

[238] M. Li, W. Wu, Z. Ma, et al., “Atraric Acid Alleviates Chronic Intermittent Hypoxia-induced Renal Fibrosis by Inhibiting Oxidative Stress and Ferroptosis in Obstructive Sleep Apnea Mice Through the Nrf2/GPX4 Pathway,” Cell Signalling 135 (2025): 112040.

[239] M. Li, W. Wu, B. Hu, et al., “Atraric Acid Activates the FoxO3a/PINK1/Parkin Signaling Pathway to Suppress Chronic Intermittent Hypoxia-induced Cardiac Oxidative Stress, Inflammatory Responses, and NLRP3 Inflammasome Activation,” Chemico-Biological Interactions 421 (2025): 111773.

[240] H. Hosseini, M. Homayouni-Tabrizi, H. Amiri, et al., “The Effect of Continuous Positive Airway Pressure on Total Antioxidant Capacity in Obstructive Sleep Apnea: A Systematic Review and Meta-analysis,” Sleep & Breathing = Schlaf & Atmung 27, no. 4 (2023): 1237–1245.

[241] F. Chen, L. Lyu, C. Xing, et al., “The Pivotal Role of TGF-β/Smad Pathway in Fibrosis Pathogenesis and Treatment,” Frontiers in Oncology 15 (2025): 1649179.

[242] R. M. Liu and L. P. Desai, “Reciprocal Regulation of TGF-β and Reactive Oxygen Species: A Perverse Cycle for Fibrosis,” Redox Biology 6 (2015): 565–577.

[243] J. Choi, Y. Kim, H. N. I. Abeysiriwardhana, et al., “Oxidative Hypoxia Drives TGF-β1-induced Fibrosis Under Normoxia,” Redox Biology 89 (2026): 103947.

[244] C. C. Lin, S. F. Liaw, C. H. Chiu, and M. W. Lin, “Effects of Continuous Positive Airway Pressure on Exhaled Transforming Growth Factor-β and Vascular Endothelial Growth Factor in Patients With Obstructive Sleep Apnea,” Journal of thoracic disease 12, no. 3 (2020): 932–941.

[245] C. Cubillos-Zapata, M. Á. Martínez-García, E. Díaz-García, et al., “Obesity Attenuates the Effect of Sleep Apnea on Active TGF-ß1 Levels and Tumor Aggressiveness in Patients With Melanoma,” Scientific Reports 10, no. 1 (2020): 15528.

[246] E. Hernández-Jiménez, C. Cubillos-Zapata, and V. Toledano, “Monocytes Inhibit NK Activity via TGF-β in Patients With Obstructive Sleep Apnoea,” European Respiratory Journal 49, no. 6 (2017): 1602456.

[247] G. Zhou, L. A. Dada, M. Wu, et al., “Hypoxia-induced Alveolar Epithelial-mesenchymal Transition Requires Mitochondrial ROS and Hypoxia-inducible Factor 1,” American Journal of Physiology. Lung Cellular and Molecular Physiology 297, no. 6 (2009): L1120–L1130.

[248] E. Díaz-García, A. García-Sánchez, D. Sánz-Rubio, et al., “SMAD4 Expression in Monocytes as a Potential Biomarker for Atherosclerosis Risk in Patients With Obstructive Sleep Apnea,” International Journal of Molecular Sciences 24, no. 9 (2023): 7900.

[249] F. Tosun, C. Babayiğit, N. Dikmen, S. Doğan, and E. Dirican, “The Effect of Continuous Positive Airway Pressure Treatment on Inflammatory Parameters and Periostin Levels in Patients With Obstructive Sleep Apnea Syndrome,” Sleep & Breathing = Schlaf & Atmung 27, no. 1 (2023): 275–282.

[250] I. Cucoranu, R. Clempus, A. Dikalova, et al., “NAD(P)H Oxidase 4 Mediates Transforming Growth Factor-beta1-induced Differentiation of Cardiac Fibroblasts Into Myofibroblasts,” Circulation Research 97, no. 9 (2005): 900–907.

[251] C. D. Bondi, N. Manickam, D. Y. Lee, et al., “NAD(P)H Oxidase Mediates TGF-beta1-induced Activation of Kidney Myofibroblasts,” Journal of the American Society of Nephrology 21, no. 1 (2010): 93–102.

[252] J. Y. F. Chung, M. K. K. Chan, J. S. F. Li, et al., “TGF-β Signaling: From Tissue Fibrosis to Tumor Microenvironment,” IJMS 22, no. 14 (2021): 7575.

[253] G. S. Schultz and A. Wysocki, “Interactions Between Extracellular Matrix and Growth Factors in Wound Healing,” Wound Repair Regeneration 17, no. 2 (2009): 153–162.

[254] E. Papakonstantinou, A. J. Aletras, M. Roth, M. Tamm, and G. Karakiulakis, “Hypoxia Modulates the Effects of Transforming Growth Factor-beta Isoforms on Matrix-formation by Primary human Lung Fibroblasts,” Cytokine 24, no. 1-2 (2003): 25–35.

[255] M. C. Pau, A. Zinellu, A. A. Mangoni, et al., “Evaluation of Inflammation and Oxidative Stress Markers in Patients With Obstructive Sleep Apnea (OSA),” JCM 12, no. 12 (2023): 3935.

[256] S. Wang, X. M. Meng, Y. Y. Ng, et al., “TGF-β/Smad3 Signalling Regulates the Transition of Bone Marrow-derived Macrophages Into Myofibroblasts During Tissue Fibrosis,” Oncotarget 7, no. 8 (2016): 8809–8822.

[257] C. Yu, Y. Liu, L. Sun, et al., “Chronic Obstructive Sleep Apnea Promotes Aortic Remodeling in Canines Through miR-145/Smad3 Signaling Pathway,” Oncotarget 8, no. 23 (2017): 37705–37716.

[258] B. Santos, B. Ramalho, A. Relógio, C. Cavadas, L. S. Gaspar, and A. R. Álvaro, “Systematic Review of Changes in Extracellular Vesicles Associated With Obstructive Sleep Apnoea: Implications for Diagnosis and Treatment,” European Respiratory Review 34, no. 178 (2025): 250073.

[259] A. Khalyfa, J. M. Marin, D. Sanz-Rubio, Z. Lyu, T. Joshi, and D. Gozal, “Multi-Omics Analysis of Circulating Exosomes in Adherent Long-Term Treated OSA Patients,” IJMS 24, no. 22 (2023): 16074.

[260] Y. Tian, D. Zhang, H. Yang, X. Zhang, and S. Xu, “Impact of FASN-enriched EVs on Endothelial Cell Function in Obstructive Sleep Apnea Hypopnea Syndrome,” Journal of Pharmaceutical Analysis 15, no. 5 (2025): 101251.

[261] S. Recoquillon, S. Ali, G. Justeau, et al., “Small Extracellular Vesicles Harboring PD-L1 in Obstructive Sleep Apnea,” IJMS 25, no. 6 (2024): 3208.

[262] J. A. Welsh, D. C. I. Goberdhan, and L. O'Driscoll, “Minimal Information for Studies of Extracellular Vesicles (MISEV2023): From Basic to Advanced Approaches,” Journal of Extracellular Vesicles 13, no. 2 (2024): e12404.

[263] W. Y. Wang, Z. J. Chen, Y. J. Lai, et al., “Exosomal miR-320b Regulates Cardiomyocyte FOXM1 Expression and May Serve as an Early-stage Compensatory Mechanism in Obstructive Sleep Apnea. Fan C, Ed,” PLoS ONE 20, no. 9 (2025): e0332862.

[264] M. Badran and D. Gozal, “Intermittent Hypoxia as a Model of Obstructive Sleep Apnea: Present and Future,” Sleep Medicine Clinics 20, no. 1 (2025): 93–102.

[265] S. E. Drummond, D. P. Burns, S. El Maghrani, O. Ziegler, V. Healy, and K. D. O'Halloran, “Chronic Intermittent Hypoxia-Induced Diaphragm Muscle Weakness Is NADPH Oxidase-2 Dependent,” Cells 12, no. 14 (2023): 1834.

[266] F. Y. Lu, X. X. Chen, M. Y. Li, et al., “Chronic Intermittent Hypoxia Exacerbates the Progression of NAFLD via SPP1-mediated Inflammatory Polarization in Macrophages,” Free Radical Biology and Medicine 238 (2025): 261–274.

[267] Q. Liu, Y. Ou, T. Liu, et al., “Preliminary Evidence of Immune Infiltration and Neutrophil Degranulation in Peripheral Blood of Non-obese OSA Patients Related to Cognitive Decline,” Scientific Reports 15, no. 1 (2025): 3481.

[268] Y. Sun, M. Zhang, S. Li, H. Huang, and X. Wu, “Diesel Exhaust Particles Exaggerate Chronic Intermittent Hypoxia-induced Lung Neutrophil Infiltration Through CXCL5 and CCL5 in Mice,” Respiratory Medicine 251 (2026): 108548.

[269] M. B. Müller, C. Stihl, A. Schmid, et al., “A Novel OSA-related Model of Intermittent Hypoxia in Endothelial Cells Under Flow Reveals Pronounced Inflammatory Pathway Activation,” Frontiers in Physiology 14 (2023): 1108966.

[270] S. N. Hong, A. Jo, and J. A. Park, “CPAP Therapy Alters Monocyte Activation and Immune Phenotype in Obstructive Sleep Apnea in Relation to Hypoxic Burden,” Clinical and Experimental Otorhinolaryngology 19, no. 2 (2026): 177–184, Published online November 17, 2025.

[271] Q. Zhu, Q. Luo, Z. Wang, S. Chen, G. Chen, and S. Huang, “Effects of Continuous Positive Airway Pressure Therapy on Inflammatory Markers in Patients With Obstructive Sleep Apnea: A Meta-analysis of Randomized Controlled Trials,” Sleep & Breathing = Schlaf & Atmung 29, no. 2 (2025): 182.

[272] M. Á. Hernández-García, B. Aldave-Orzáiz, C. E. Fernández-García, et al., “Normalization of Oxygen Levels Induces a Metabolic Reprogramming in Livers Exposed to Intermittent Hypoxia Mimicking Obstructive Sleep Apnea,” Antioxidants (Basel) 14, no. 8 (2025): 971.

[273] Z. Shi, L. Xu, H. Xie, et al., “Attenuation of Intermittent Hypoxia-induced Apoptosis and Fibrosis in Pulmonary Tissues via Suppression of ER Stress Activation,” BMC Pulmonary Medicine 20, no. 1 (2020): 92.

[274] L. Ran, C. Wei, X. Wang, et al., “SPHK2 inhibition Alleviates Chronic Intermittent Hypoxia-induced Inflammation in Adipose Tissue by Decreasing Endoplasmic Reticulum Stress,” European Journal of Pharmacology 1002 (2025): 177841.

[275] V. C. Auyeung, T. L. Steinberg, A. Olivier, et al., “Pharmacologic Inhibition of IRE1α-dependent Decay Protects Alveolar Epithelial Identity and Prevents Pulmonary Fibrosis in Mice,” Journal of Clinical Investigation 135, no. 20 (2025): e184522.

[276] T. Tobushi and J. S. Floras, “Sleep Apnea, Autonomic Disturbances, and Blood Pressure Variability,” Hypertension 81, no. 9 (2024): 1837–1844.

[277] A. K. Ikeda and R. Mehra, “Obstructive Sleep Apnea and Hypertension: Is Aldosterone Blockade the Optimal Approach to Control Blood Pressure and Improve Oxygenation?,” Current Hypertension Reports 28, no. 1 (2026): 6.

[278] S. Tang, Q. Li, H. Yang, and Y. Liu, “Causal Associations between Obstructive Sleep Apnea and Hypertension: Evidence from a Bidirectional and Multivariable Mendelian Randomization Analysis,” International Journal of Hypertension 2025 (2025): 8814506.

[279] L. Benning, J. J. Herzig, M. S. Mollet, et al., “Effects of CPAP on Blood Pressure Parameter across Different Severities of Obstructive Sleep Apnoea: A Meta-Analysis,” Journal of Sleep Research 34, no. 5 (2025): e70072.

[280] Y. H. Ou, J. T. Colpani, C. S. Cheong, et al., “Mandibular Advancement vs CPAP for Blood Pressure Reduction in Patients with Obstructive Sleep Apnea,” Journal of the American College of Cardiology 83, no. 18 (2024): 1760–1772.

[281] R. C. Dedhia, D. L. Bliwise, A. A. Quyyumi, et al., “Hypoglossal Nerve Stimulation and Cardiovascular Outcomes for Patients with Obstructive Sleep Apnea: A Randomized Clinical Trial,” JAMA Otolaryngology – Head & Neck Surgery 150, no. 1 (2024): 39.

[282] Y. Kwon, W. S. Tzeng, J. Seo, et al., “Obstructive Sleep Apnea and Hypertension; Critical Overview,” Clinical Hypertension 30, no. 1 (2024): 19.

[283] K. Shiina, “Obstructive Sleep Apnea -related Hypertension: A Review of the Literature and Clinical Management Strategy,” Hypertension Research 47, no. 11 (2024): 3085–3098.

[284] N. R. Prabhakar, Y. J. Peng, and J. Nanduri, “Carotid Body Hypersensitivity in Intermittent Hypoxia and Obtructive Sleep Apnoea,” Journal De Physiologie 601, no. 24 (2023): 5481–5494.

[285] M. F. Pengo, E. I. Schwarz, F. Barbé, et al., “Effect of CPAP Therapy on Blood Pressure in Patients With Obstructive Sleep Apnoea: A Worldwide Individual Patient Data Meta-analysis,” European Respiratory Journal 65, no. 1 (2025): 2400837.

[286] S. Daneshvar, E. Seyedrezazadeh, M. Seyyedi, et al., “Evaluating the Endothelial and Metabolic Effects of CPAP Therapy in Obstructive Sleep Apnea Patients: Insights From a Comprehensive Meta-analysis,” Sleep Medicine Reviews 84 (2025): 102187.

[287] Y. Peker, Y. Celik, A. Zinchuk, S. A. Sands, S. Redline, and A. Azarbarzin, “Association of Hypoxic Burden with Cardiovascular Events,” Chest 168, no. 6 (2025): 1481–1493.

[288] D. R. Mazzotti, L. R. Waitman, J. Miller, et al., “Positive Airway Pressure, Mortality, and Cardiovascular Risk in Older Adults with Sleep Apnea,” JAMA Network Open 7, no. 9 (2024): e2432468.

[289] A. V. Benjafield, J. L. Pepin, P. A. Cistulli, et al., “Positive Airway Pressure Therapy and all-cause and Cardiovascular Mortality in People With Obstructive Sleep Apnoea: A Systematic Review and Meta-analysis of Randomised Controlled Trials and Confounder-adjusted, Non-randomised Controlled Studies,” The Lancet Respiratory Medicine 13, no. 5 (2025): 403–413.

[290] J. A. Joglar, M. K. Chung, A. L. Armbruster, et al., “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines,” Circulation 149, no. 1 (2024): e1–e156.

[291] I. C. Van Gelder, M. Rienstra, K. V. Bunting, et al., “2024 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With the European Association for Cardio-Thoracic Surgery (EACTS),” European Heart Journal 45, no. 36 (2024): 3314–3414.

[292] J. Fan, C. J. Tan, L. L. Cao, et al., “The Impact of Continuous Positive Airway Pressure Therapy on the Recurrence of Atrial Fibrillation in Patients With Obstructive Sleep Apnea After Pulmonary Vein Isolation,” BMC Cardiovascular Disorders [Electronic Resource] 25, no. 1 (2025): 473.

[293] X. Zou, X. Zhou, and S. Yi, “Obstructive Sleep Apnea and the Risk of Sudden Cardiac Death: A Systematic Review and Meta-analysis,” BMC Cardiovascular Disorders [Electronic Resource] 25, no. 1 (2025): 751.

[294] C. J. Nalliah, G. R. Wong, G. Lee, et al., “Impact of CPAP on the Atrial Fibrillation Substrate in Obstructive Sleep Apnea: The SLEEP-AF Study,” JACC Clinical Electrophysiology 8, no. 7 (2022): 869–877.

[295] N. Tanaka, M. Okada, K. Tanaka, et al., “Impact of Long-Term CPAP Adherence on Recurrence after Atrial Fibrillation Ablation in Patients with Severe Sleep Apnea,” Journal of the American Heart Association 14, no. 10 (2025): e038742.

[296] Z. A. Toh, L. J. Cheng, X. V. Wu, et al., “Positive Airway Pressure Therapy for Post-stroke Sleep Disordered Breathing: A Systematic Review, Meta-analysis and Meta-regression,” European Respiratory Review 32, no. 167 (2023): 220169.

[297] A. T. Siddiquee, Y. H. Hwang, S. Kim, et al., “Obstructive Sleep Apnea and Cerebral Microbleeds in Middle-Aged and Older Adults,” JAMA Network Open 8, no. 10 (2025): e2539874.

[298] S. A. Ward, E. Storey, M. T. Naughton, et al., “Obstructive Sleep Apnea and Cerebral Small Vessel Disease in Community-based Older People: An aspirin in Reducing Events in the Elderly Imaging Substudy,” Sleep 48, no. 2 (2025): zsae204.

[299] J. Suusgaard, A. S. West, L. B. Ponsaing, H. K. Iversen, K. Rauen, and P. J. Jennum, “Stroke Recurrence and all-cause Mortality in CPAP-treated Sleep-disordered-breathing Patients,” Journal of Stroke and Cerebrovascular Diseases 34, no. 2 (2025): 108204.

[300] J. Wang, A. Subramanian, N. Cockburn, J. Xiao, K. Nirantharakumar, and S. Haroon, “Obstructive Sleep Apnoea Syndrome and Future Risk of Dementia Among Individuals Managed in UK General Practice,” Thorax 80, no. 3 (2025): 167.

[301] I. Mohammadi, M. Adibparsa, A. Najafi, M. S. Sehat, and M. Sadeghi, “A Systematic Review With Meta-analysis to Assess Alzheimer's Disease Biomarkers in Adults With or Without Obstructive Sleep Apnoea,” International Orthodontics 21, no. 4 (2023): 100814.

[302] R. Sommer, E. A. Hill, J. Ramirez, et al., “Continuous Positive Airway Pressure and Progression of Enlarged Perivascular Spaces in Adults with Obstructive Sleep Apnea,” Neurology 105, no. 8 (2025): e213955.

[303] N. A. Marchi, G. Allali, and R. Heinzer, “Obstructive Sleep Apnea, Cognitive Impairment, and Dementia: Is Sleep Microstructure an Important Feature?,” Sleep 47, no. 12 (2024): zsae161.

[304] W. Cui, Z. Duan, Z. Li, and J. Feng, “Assessment of Alzheimer's Disease-related Biomarkers in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-analysis,” Frontiers in aging neuroscience 14 (2022): 902408.

[305] M. Guay-Gagnon, S. Vat, M. F. Forget, et al., “Sleep Apnea and the Risk of Dementia: A Systematic Review and Meta-analysis,” Journal of Sleep Research 31, no. 5 (2022): e13589.

[306] K. H. Franks, E. Rowsthorn, J. Nicolazzo, et al., “The Treatment of Sleep Dysfunction to Improve Cognitive Function: A Meta-analysis of Randomized Controlled Trials,” Sleep Medicine 101 (2023): 118–126.

[307] C. M. Hoyos, N. E. Cross, Z. Terpening, et al., “Continuous Positive Airway Pressure for Cognition in Sleep Apnea and Mild Cognitive Impairment: A Pilot Randomized Crossover Clinical Trial,” American Journal of Respiratory and Critical Care Medicine 205, no. 12 (2022): 1479–1482.

[308] J. W. Sun, H. C. Hsu, J. S. Wu, et al., “Sleep Apnea in Interstitial Lung Disease: A Systematic Review and Meta-analysis of Prevalence, Severity, and Risk Factors,” Sleep Medicine 136 (2025): 106768.

[309] A. V. Cardoso, N. Pereira, I. Neves, et al., “Obstructive Sleep Apnoea in Patients With Fibrotic Diffuse Parenchymal Lung Disease-characterization and Treatment Compliance Assessment,” Canadian Journal of Respiratory Therapy 54, no. 2 (2018): 35–40.

[310] A. Patsoura, G. Baldini, D. Puggioni, et al., “The Link between Sleep-Related Breathing Disorders and Idiopathic Pulmonary Fibrosis: Pathophysiological Mechanisms and Treatment Options-A Review,” Journal of Clinical Medicine 14, no. 7 (2025): 2205.

[311] K. J. Myall, A. G. West, J. L. Martinovic, et al., “Nocturnal Hypoxemia Associates with Symptom Progression and Mortality in Patients with Progressive Fibrotic Interstitial Lung Disease,” Chest 164, no. 5 (2023): 1232–1242.

[312] L. Hagmeyer, S. D. Herkenrath, M. Treml, A. Pietzke-Calcagnile, N. Anduleit, and W. Randerath, “Sleep-related Breathing Disorders in Idiopathic Pulmonary Fibrosis Are Frequent and May be Associated With Pulmonary Vascular Involvement,” Sleep & Breathing = Schlaf & Atmung 27, no. 3 (2023): 961–971.

[313] D. Valecchi, E. Bargagli, M. G. Pieroni, et al., “Prognostic Significance of Obstructive Sleep Apnea in a Population of Subjects With Interstitial Lung Diseases,” Pulmonary Therapy 9, no. 2 (2023): 223–236.

[314] P. R. Genta and P. Mariano, “Understanding the Link Between Interstitial Lung Disease and Obstructive Sleep Apnea: Is Lung Volume Involved?,” Jornal Brasileiro de Pneumologia 50, no. 5 (2024): e20240356.

[315] H. Lee, I. K. Kim, J. Im, et al., “Effects of Aging on Accompanying Intermittent Hypoxia in a Bleomycin-induced Pulmonary Fibrosis Mouse Model,” Korean Journal of Internal Medicine 38, no. 6 (2023): 934–944.

[316] J. S. Kim, A. Azarbarzin, A. J. Podolanczuk, et al., “Obstructive Sleep Apnea and Longitudinal Changes in Interstitial Lung Imaging and Lung Function: The MESA Study,” Annals of the American Thoracic Society 20, no. 5 (2023): 728–737.

[317] T. C. Wang, T. C. Shen, C. L. Lin, and C. Y. Hsu, “Risk of Obstructive Sleep Apnea in Idiopathic Pulmonary Fibrosis,” European Journal of Internal Medicine 110 (2023): 120–121.

[318] G. Raghu, M. Remy-Jardin, L. Richeldi, et al., “Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline,” American Journal of Respiratory and Critical Care Medicine 205, no. 9 (2022): e18–e47.

[319] J. A. Mackintosh, G. Keir, L. K. Troy, et al., “Treatment of Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis: A Position Statement From the Thoracic Society of Australia and New Zealand 2023 Revision,” Respirology 29, no. 2 (2024): 105–135.

[320] N. Srivali, C. Thongprayoon, and W. Cheungpasitporn, “Assessing the Impact of Continuous Positive Airway Pressure Therapy on Clinical Outcomes in Interstitial Lung Disease Patients With Coexisting Obstructive Sleep Apnea: A Systematic Review,” Sleep & Breathing = Schlaf & Atmung 28, no. 4 (2024): 1617–1624.

[321] C. Mermigkis, I. Bouloukaki, and S. E. Schiza, “Sleep as a New Target for Improving Outcomes in Idiopathic Pulmonary Fibrosis,” Chest 152, no. 6 (2017): 1327–1338.

[322] G. Papadogiannis, I. Bouloukaki, C. Mermigkis, et al., “Patients With Idiopathic Pulmonary Fibrosis With and Without Obstructive Sleep Apnea: Differences in Clinical Characteristics, Clinical Outcomes, and the Effect of PAP Treatment,” Journal of Clinical Sleep Medicine 17, no. 3 (2021): 533–544.

[323] I. Bouloukaki, S. Michelakis, E. Tsitoura, et al., “KL-6, ET-1 and S100A9 Levels in Patients With Idiopathic Pulmonary Fibrosis and Obstructive Sleep Apnea,” Experimental and Therapeutic Medicine 29, no. 1 (2024): 16.

[324] M. E. Rinella, J. V. Lazarus, V. Ratziu, et al., “A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature,” Journal of Hepatology 79, no. 6 (2023): 1542–1556.

[325] O. A. Mesarwi, R. Loomba, and A. Malhotra, “Obstructive Sleep Apnea, Hypoxia, and Nonalcoholic Fatty Liver Disease,” American Journal of Respiratory and Critical Care Medicine 199, no. 7 (2019): 830–841.

[326] H. Kan, L. Chen, Z. Yang, and S. Zhu, “Relationship Between Obstructive Sleep Apnea-hypopnea Syndrome (OSAHS) and Liver Fibrosis,” Family Medicine and Community Health 2, no. 3 (2014): 7–11.

[327] Z. W. Zhao, W. S. Huang, L. Li, L. D. Chen, L. Lin, and H. X. Zeng, “Association Between Sleep Apnea and Ultrasound-defined Liver Fibrosis: Results From NHANES 2017 to 2020,” Medicine 103, no. 17 (2024): e37949.

[328] S. Bettini, R. Serra, R. Fabris, et al., “Association of Obstructive Sleep Apnea With Non-alcoholic Fatty Liver Disease in Patients With Obesity: An Observational Study,” Eating and Weight Disorders 27, no. 1 (2022): 335–343.

[329] P. Landete, C. E. Fernández-García, B. Aldave-Orzaiz, et al., “Increased Oxygen Desaturation Time during Sleep Is a Risk Factor for NASH in Patients with Obstructive Sleep Apnea: A Prospective Cohort Study,” Frontiers in Medicine (Lausanne) 9 (2022): 808417.

[330] S. Petta, O. Marrone, D. Torres, et al., “Obstructive Sleep Apnea Is Associated With Liver Damage and Atherosclerosis in Patients With Non-Alcoholic Fatty Liver Disease,” PLoS ONE 10, no. 12 (2015): e0142210.

[331] Z. Zhang, M. Li, G. Ji, and L. Zhang, “Causal Relationship Between Sleep Apnea and Non-alcoholic Fatty Liver Disease: A Mendelian Randomization Study,” European Journal of Clinical Investigation 54, no. 3 (2024): e14116.

[332] H. A. Jawa, H. Khatib, N. Alzahrani, et al., “Nonalcoholic Fatty Liver Disease and Fibrosis Risk in Patients with Obstructive Sleep Apnea: A Retrospective Analysis,” Cureus 13, no. 2 (2021): e13623.

[333] T. Kim, H. Choi, J. Lee, and J. Kim, “Obstructive Sleep Apnea and Nonalcoholic Fatty Liver Disease in the General Population: A Cross-Sectional Study Using Nationally Representative Data,” IJERPH 19, no. 14 (2022): 8398.

[334] I. Umbro, V. Fabiani, M. Fabiani, F. Angelico, and M. D. Ben, “Association Between Non-alcoholic Fatty Liver Disease and Obstructive Sleep Apnea,” WJG 26, no. 20 (2020): 2669–2681.

[335] A. Briançon-Marjollet, M. Netchitaïlo, F. Fabre, et al., “Intermittent Hypoxia Increases Lipid Insulin Resistance in Healthy Humans: A Randomized Crossover Trial,” Journal of Sleep Research 34, no. 2 (2025): e14243.

[336] J. L. Fernandes, F. O. Martins, E. Olea, et al., “Chronic Intermittent Hypoxia-Induced Dysmetabolism Is Associated With Hepatic Oxidative Stress, Mitochondrial Dysfunction and Inflammation,” Antioxidants 12, no. 11 (2023): 1910.

[337] Y. Ji, Y. Liang, P. H. Chu, et al., “The Effects of Intermittent Hypoxia on Hepatic Expression of Fatty Acid Translocase CD36 in Lean and Diet-induced Obese Mice,” Biomed J 46, no. 5 (2023): 100566.

[338] H. H. Kang, I. K. Kim, H. I. Lee, et al., “Chronic Intermittent Hypoxia Induces Liver Fibrosis in Mice With Diet-induced Obesity via TLR4/MyD88/MAPK/NF-kB Signaling Pathways,” Biochemical and Biophysical Research Communications 490, no. 2 (2017): 349–355.

[339] Y. Li, Y. Chen, X. Xiao, S. Deng, J. Kuang, and Y. Wang, “CX3CL1 represses Autophagy via CX3CR1/CaMKIIδ/HDAC4/Rubicon Axis and Exacerbates Chronic Intermittent Hypoxia Induced Kupffer Cell Apoptosis,” Cellular Signalling 111 (2023): 110873.

[340] K. Kou, S. Li, W. Qiu, Z. Fan, M. Li, and G. Lv, “Hypoxia-inducible Factor 1α/IL-6 Axis in Activated Hepatic Stellate Cells Aggravates Liver Fibrosis,” Biochemical and Biophysical Research Communications 653 (2023): 21–30.

[341] O. A. Mesarwi, M. K. Shin, L. F. Drager, et al., “Lysyl Oxidase as a Serum Biomarker of Liver Fibrosis in Patients With Severe Obesity and Obstructive Sleep Apnea,” Sleep 38, no. 10 (2015): 1583–1591.

[342] J. Xiong, Y. Xu, N. Wang, et al., “Obstructive Sleep Apnea Syndrome Exacerbates NASH Progression via Selective Autophagy-Mediated Eepd1 Degradation,” Advanced Science 11, no. 35 (2024): 2405955.

[343] W. Cai, S. Wu, X. Ming, et al., “IL6 Derived From Macrophages Under Intermittent Hypoxia Exacerbates NAFLD by Promoting Ferroptosis via MARCH3-Led Ubiquitylation of GPX4,” Advanced Science 11, no. 41 (2024): 2402241.

[344] Q. Li, T. Xu, C. Shao, et al., “Obstructive Sleep Apnea Is Related to Alterations in Fecal Microbiome and Impaired Intestinal Barrier Function,” Scientific Reports 13, no. 1 (2023): 778.

[345] A. Parchani, R. Gupta, R. Kant, L. K. Saini, and R. Gupta, “Evaluation of Hepatic Steatosis and Fibrosis Using Transient Elastography in Patients with Obstructive Sleep Apnea,” Journal of Clinical and Experimental Hepatology 14, no. 2 (2024): 101289.

[346] S. S. S. Ng, V. W. S. Wong, G. L. H. Wong, et al., “Continuous Positive Airway Pressure Does Not Improve Nonalcoholic Fatty Liver Disease in Patients With Obstructive Sleep Apnea. A Randomized Clinical Trial,” American Journal of Respiratory and Critical Care Medicine 203, no. 4 (2021): 493–501.

[347] M. E. Rinella, B. A. Neuschwander-Tetri, M. S. Siddiqui, et al., “AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease,” Hepatology 77, no. 5 (2023): 1797–1835.

[348] A. E. Beaudin, J. K. Raneri, S. B. Ahmed, et al., “Risk of Chronic Kidney Disease in Patients With Obstructive Sleep Apnea,” Sleep 45, no. 2 (2022): zsab267.

[349] Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group., “KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease,” Kidney International 105, no. 4S (2024): S117–S314.

[350] S. M. Jung and M. R. Lee, “Association Between Obstructive Sleep Apnea and Chronic Kidney Disease According to Sex, Long Working Hours: The Korean National Health and Nutrition Examination Survey (2019–2020),” Life 13, no. 8 (2023): 1625.

[351] M. Liu, M. Heizhati, N. Li, et al., “Association Between Obstructive Sleep Apnea and 24-h Urine Protein Quantification in Patients With Hypertension,” Scientific Reports 14, no. 1 (2024): 20876.

[352] S. Driendl, S. Stadler, M. Baumert, et al., “Nocturnal Hypoxemic Burden Is Associated With Worsening Prognosis of Chronic Kidney Disease in Patients With Type 2 Diabetes,” Cardiovascular Diabetology 24, no. 1 (2025): 354.

[353] A. E. Beaudin, J. K. Raneri, S. B. Ahmed, et al., “Nocturnal Hypoxemia Is Associated With Increased Urine Kidney Injury Molecule-1 (KIM-1) in Patients With Obstructive Sleep Apnea,” Journal of Clinical Sleep Medicine 22, no. 1 (2026): 9.

[354] C. H. Park and T. H. Yoo, “TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis,” Pharmaceuticals 15, no. 12 (2022): 1485.

[355] C. Bai, Y. Zhu, Q. Dong, and Y. Zhang, “Chronic Intermittent Hypoxia Induces the Pyroptosis of Renal Tubular Epithelial Cells by Activating the NLRP3 Inflammasome,” Bioengineered 13, no. 3 (2022): 7528–7540.

[356] K. W. Kious, K. A. Savage, S. C. E. Twohey, et al., “Chronic Intermittent Hypoxia Promotes Glomerular Hyperfiltration and Potentiates Hypoxia-evoked Decreases in Renal Perfusion and PO2,” Frontiers in Physiology 14 (2023): 1235289.

[357] H. H. Peng, C. E. Hu, Y. L. Wu, W. T. Liu, C. Y. Tsai, and Y. C. Kuan, “Effects of Continuous Positive Airway Pressure on Renal Function in Adults With Obstructive Sleep Apnea: A Systematic Review and Meta-analysis,” Sleep & Breathing = Schlaf & Atmung 29, no. 1 (2025): 102.

[358] Y. Peker, B. Akdeniz, S. Altay, et al., “Obstructive Sleep Apnea and Cardiovascular Disease: Where Do We Stand?,” Anatolian Journal of Cardiology 27, no. 7 (2023): 375–389.

[359] S. Wang, H. Cui, K. Ji, et al., “Relationship between Obstructive Sleep Apnea and Late Gadolinium Enhancement and Their Effect on Cardiac Arrhythmias in Patients With Hypertrophic Obstructive Cardiomyopathy,” NSS 13 (2021): 447–456.

[360] M. Jaafar, A. Godhamgaonkar, S. Alsanjari, and M. Protty, “The Role of Cardiac Magnetic Resonance Imaging in Obstructive Sleep Apnea: A Systematic Scoping Review,” Journal of Clinical Sleep Medicine 21, no. 9 (2025): 1627–1638.

[361] Y. Takada, K. Shiina, S. Orihara, et al., “Intermittent Hypoxia by Obstructive Sleep Apnea Is Significantly Associated With Electro-anatomical Remodeling of the Left Atrium Preceding Structural Remodeling in Patients With Atrial Fibrillation,” IJC Heart & Vasculature 54 (2024): 101490.

[362] T. Li, Q. Ou, X. Zhou, et al., “Left Ventricular Remodeling and Systolic Function Changes in Patients With Obstructive Sleep Apnea: A Comprehensive Contrast-enhanced Cardiac Magnetic Resonance Study,” Cardiovascular Diagnosis and Therapy 12, no. 4 (2022): 436–452.

[363] S. Ryan, “Mechanisms of Cardiovascular Disease in Obstructive Sleep Apnoea,” Journal of Thoracic Disease 10, no. S34 (2018): S4201–S4211.

[364] L. Lavie and V. Polotsky, “Cardiovascular Aspects in Obstructive Sleep Apnea Syndrome – Molecular Issues, Hypoxia and Cytokine Profiles,” Respiration 78, no. 4 (2009): 361–370.

[365] V. K. Somers, D. P. White, R. Amin, et al., “Sleep Apnea and Cardiovascular Disease: An American Heart Association/american College Of Cardiology Foundation Scientific Statement From the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In Collaboration With the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health),” Circulation 118, no. 10 (2008): 1080–1111.

[366] L. Liu, Y. Wang, L. Hong, N. L. Bragazzi, H. Dai, and H. Chen, “Obstructive Sleep Apnea and Hypertensive Heart Disease: From Pathophysiology to Therapeutics,” Reviews in Cardiovascular Medicine 24, no. 12 (2023): 342.

[367] P. Ramos, C. Rubies, M. Torres, et al., “Atrial Fibrosis in a Chronic Murine Model of Obstructive Sleep Apnea: Mechanisms and Prevention by Mesenchymal Stem Cells,” Respiratory Research 15, no. 1 (2014): 54.

[368] X. Xu, P. H. Zhen, F. C. Yu, et al., “Chronic Intermittent Hypoxia Accelerates Cardiac Dysfunction and Cardiac Remodeling During Cardiac Pressure Overload in Mice and Can be Alleviated by PHD3 Overexpression,” Frontiers in Cardiovascular Medicine 9 (2022): 974345.

[369] Z. Zhou, Q. Zhao, Y. Huang, et al., “Berberine Ameliorates Chronic Intermittent Hypoxia-induced Cardiac Remodelling by Preserving Mitochondrial Function, Role of SIRT6 Signalling,” J Cellular Molecular Medi 28, no. 12 (2024): e18407.

[370] M. Tadic, E. Gherbesi, A. Faggiano, C. Sala, S. Carugo, and C. Cuspidi, “The Impact of Continuous Positive Airway Pressure on Cardiac Mechanics: Findings From a Meta-analysis of Echocardiographic Studies,” Journal of Clinical Hypertension 24, no. 7 (2022): 795–803.

[371] P. De Coelho Castro, V. M. Prizão, G. Erzinger, et al., “Efficacy of Continuous Positive Airway Pressure on Cardiac Remodeling and Ventricular Function in Obstructive Sleep Apnea: A Systematic Review and Updated Meta-analysis of Speckle-tracking Echocardiography,” Journal of Hypertension 44, no. 1 (2026): 16–27.

[372] L. Xu, B. T. Keenan, D. Maislin, et al., “Effect of Obstructive Sleep Apnea and Positive Airway Pressure Therapy on Cardiac Remodeling as Assessed by Cardiac Biomarker and Magnetic Resonance Imaging in Nonobese and Obese Adults,” Hypertension 77, no. 3 (2021): 980–992.

[373] T. Kasai, T. Kohno, W. Shimizu, et al., “JCS 2023 Guideline on Diagnosis and Treatment of Sleep Disordered Breathing in Cardiovascular Disease,” Circulation Journal 88, no. 11 (2024): 1865–1935.

[374] L. P. De Sousa, F. M. G. Liberato, F. M. Vendrusculo, M. V. F. Donadio, and R. R. B. Barbosa, “Obstructive Sleep Apnea in Children and Adolescents With Cystic Fibrosis and Preserved Lung Function or Mild Impairment: A Systematic Review and Meta-analysis of Prevalence,” Sleep Medicine 88 (2021): 36–43.

[375] B. Fauroux, K. Waters, and J. E. MacLean, “Sleep in Children and Young Adults With Cystic Fibrosis,” Paediatric Respiratory Reviews 46 (2023): 12–16.

[376] J. Reiter, O. Breuer, M. Cohen-Cymberknoh, E. Forno, and A. Gileles-Hillel, “Sleep in Children With Cystic Fibrosis: More Under the Covers,” Pediatric Pulmonology 57, no. 8 (2022): 1944–1951.

[377] A. Shakkottai, S. Kim, and R. B. Mitchell, “Obstructive Sleep Apnea in Children With Cystic Fibrosis on Highly Effective Modulator Therapy,” Pediatric Pulmonology 59, no. 10 (2024): 2535–2542.

[378] M. Welsner, S. Dietz-Terjung, F. Stehling, et al., “Obstructive Sleep Apnea and Nocturnal Hypoxemia in Adult Patients With Cystic Fibrosis,” BMC Pulmonary Medicine 22, no. 1 (2022): 446.

[379] A. Maqsood, X. Ma, E. Tullis, et al., “Sleep Breathing Disorder Frequency, Risk Factors, and Treatment Among Adults With Cystic Fibrosis,” Journal of Cystic Fibrosis 23, no. 1 (2024): 144–149.

[380] M. Welsner, T. Schulte, S. Dietz-Terjung, et al., “Effect of Triple Combination CFTR Modulator Therapy on Sleep in Adult Patients With Cystic Fibrosis,” Respiration 101, no. 8 (2022): 766–774.

[381] J. Krajewska, K. Zub, A. Słowikowski, and T. Zatoński, “Chronic Rhinosinusitis in Cystic Fibrosis: A Review of Therapeutic Options,” European Archives of Oto-Rhino-Laryngology 279, no. 1 (2022): 1–24.

[382] M. Welsner, S. Dietz-Terjung, S. Strassburg, et al., “Paranasal Sinus CT and Polysomnographic Findings in Adults With Cystic Fibrosis: Implications for Obstructive Sleep Apnea,” Pathophysiology 33, no. 1 (2026): 6.

[383] K. Bader-Larsen, B. U. Nielsen, E. Henriksen, et al., “Body Mass, Linear Growth, and Body Composition Before and After the Introduction of Elexacaftor/Tezacaftor/Ivacaftor Among Children and Adults With Cystic Fibrosis,” Clinical Nutrition 54 (2025): 132–139.

[384] A. Merino Sánchez-Cañete, C. M. López Cárdenes, S. Vicente Santamaría, et al., “Increased Fat Mass and Obesity Risk After Elexacaftor–tezacaftor–ivacaftor Therapy in Young Adults With Cystic Fibrosis,” Frontiers in Nutrition 11 (2024): 1477674.

[385] P. Faverio, U. Zanini, A. Monzani, et al., “Sleep-Disordered Breathing and Chronic Respiratory Infections: A Narrative Review in Adult and Pediatric Population,” IJMS 24, no. 6 (2023): 5504.

[386] N. S. Faria Júnior, J. J. Urbano, and I. R. Santos, “Evaluation of Obstructive Sleep Apnea in Non-cystic Fibrosis Bronchiectasis: A Cross-sectional Study. Romigi A, Ed,” PLoS ONE 12, no. 10 (2017): e0185413.

[387] S. Borekci, Y. Sekibag, et al., “The Frequency of Obstructive Sleep Apnea in Patients With Non-cystic Fibrosis Bronchiectasis,” Turkish Thoracic Journal 22, no. 4 (2021): 333–338.

[388] D. Vezir, S. Olgun Yıldızeli, D. Kocakaya, B. Ceyhan, and B. Balcan, “Frequency of Obstructive Sleep Apnea in Patients with Cystic Fibrosis and Non-cystic Fibrosis Bronchiectasis and Its Association with Clinical Findings,” Cureus 15, no. 12 (2023): e51224, Published online December 28, 2023.

[389] C. M. Mangione, M. J. Barry, et al., “Screening for Obstructive Sleep Apnea in Adults: US Preventive Services Task Force Recommendation Statement,” Jama 328, no. 19 (2022): 1945.

[390] V. K. Kapur, D. H. Auckley, S. Chowdhuri, et al., “Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline,” Journal of Clinical Sleep Medicine 13, no. 3 (2017): 479–504.

[391] A. Malhotra, I. Ayappa, N. Ayas, et al., “Metrics of Sleep Apnea Severity: Beyond the Apnea-hypopnea Index,” Sleep 44, no. 7 (2021): zsab030.

[392] M. Friedman, H. Tanyeri, M. La Rosa, et al., “Clinical Predictors of Obstructive Sleep Apnea,” The Laryngoscope 109, no. 12 (1999): 1901–1907.

[393] L. Bernhardt, E. M. Brady, S. C. Freeman, et al., “Diagnostic Accuracy of Screening Questionnaires for Obstructive Sleep Apnoea in Adults in Different Clinical Cohorts: A Systematic Review and Meta-analysis,” Sleep & Breathing = Schlaf & Atmung 26, no. 3 (2022): 1053–1078.

[394] M. Hwang, M. Nagappa, N. Guluzade, A. Saripella, M. Englesakis, and F. Chung, “Validation of the STOP-Bang Questionnaire as a Preoperative Screening Tool for Obstructive Sleep Apnea: A Systematic Review and Meta-analysis,” BMC Anesthesiol 22, no. 1 (2022): 366.

[395] K. Abu, M. L. Khraiche, and J. Amatoury, “Obstructive Sleep Apnea Diagnosis and Beyond Using Portable Monitors,” Sleep Medicine 113 (2024): 260–274.

[396] R. B. Berry, A. R. Abreu, V. Krishnan, S. F. Quan, P. J. Strollo, and R. K. Malhotra, “A Transition to the American Academy of Sleep Medicine–recommended Hypopnea Definition in Adults: Initiatives of the Hypopnea Scoring Rule Task Force,” Journal of Clinical Sleep Medicine 18, no. 5 (2022): 1419–1425.

[397] R. Mehra, D. H. Auckley, K. G. Johnson, et al., “Evaluation and Management of Obstructive Sleep Apnea in Adults Hospitalized for Medical Care: An American Academy of Sleep Medicine Clinical Practice Guideline,” Journal of Clinical Sleep Medicine 21, no. 12 (2025): 2193–2203.

[398] L. Wang, D. H. Wei, J. Zhang, and J. Cao, “Time under 90% Oxygen Saturation and Systemic Hypertension in Patients With Obstructive Sleep Apnea Syndrome,” NSS 14 (2022): 2123–2132.

[399] A. Azarbarzin, S. A. Sands, K. L. Stone, et al., “The Hypoxic Burden of Sleep Apnoea Predicts Cardiovascular Disease-related Mortality: The Osteoporotic Fractures in Men Study and the Sleep Heart Health Study,” European Heart Journal 40, no. 14 (2019): 1149–1157.

[400] A. Azarbarzin, S. A. Sands, L. Taranto-Montemurro, et al., “The Sleep Apnea-Specific Hypoxic Burden Predicts Incident Heart Failure,” Chest 158, no. 2 (2020): 739–750.

[401] T. M. Tolbert, C. N. Schmickl, L. K. Gell, et al., “Research Priorities for Translating Endophenotyping of Adult Obstructive Sleep Apnea to the Clinic: An Official American Thoracic Society Research Statement,” American Journal of Respiratory and Critical Care Medicine 211, no. 9 (2025): 1562–1583.

[402] A. De Vito, M. Carrasco Llatas, and M. J. Ravesloot, “European Position Paper on Drug-induced Sleep Endoscopy: 2017 Update,” Clinical Otolaryngology 43, no. 6 (2018): 1541–1552.

[403] Y. Qi, Y. Zhao, Y. Yan, and D. Wu, “Surgical Failure Guided by DISE in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-analysis,” European Archives of Oto-Rhino-Laryngology 281, no. 7 (2024): 3333–3343.

[404] M. Di Bari, G. Colombo, F. Giombi, et al., “The Effect of Drug-induced Sleep Endoscopy on Surgical Outcomes for Obstructive Sleep Apnea: A Systematic Review,” Sleep & Breathing = Schlaf & Atmung 28, no. 2 (2024): 859–867.

[405] A. A. Chiang, E. Jerkins, S. Holfinger, et al., “OSA Diagnosis Goes Wearable: Are the Latest Devices Ready to Shine?,” Journal of Clinical Sleep Medicine 20, no. 11 (2024): 1823–1838.

[406] A. Abd-alrazaq, H. Aslam, and R. AlSaad, “Detection of Sleep Apnea Using Wearable AI: Systematic Review and Meta-Analysis,” Journal of Medical Internet Research [Electronic Resource] 26 (2024): e58187.

[407] D. J. Gottlieb and N. M. Punjabi, “Diagnosis and Management of Obstructive Sleep Apnea: A Review,” Jama 323, no. 14 (2020): 1389.

[408] S. P. Patil, I. A. Ayappa, S. M. Caples, R. J. Kimoff, S. R. Patel, and C. G. Harrod, “Treatment of Adult Obstructive Sleep Apnea With Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline,” Journal of Clinical Sleep Medicine 15, no. 2 (2019): 335–343.

[409] J. Liao, Y. Shi, X. Gao, et al., “Efficacy of Oral Appliance for Mild, Moderate, and Severe Obstructive Sleep Apnea: A Meta-analysis,” Otolaryngology - Head and Neck Surgery 170, no. 5 (2024): 1270–1279.

[410] D. W. Hudgel, S. R. Patel, A. M. Ahasic, et al., “The Role of Weight Management in the Treatment of Adult Obstructive Sleep Apnea. An Official American Thoracic Society Clinical Practice Guideline,” American Journal of Respiratory and Critical Care Medicine 198, no. 6 (2018): e70–e87.

[411] M. J. L. Ravesloot, “Positional Treatment of Obstructive Sleep Apnea,” Otolaryngologic Clinics of North America 57, no. 3 (2024): 481–490.

[412] P. R. Srijithesh, R. Aghoram, A. Goel, and J. Dhanya, “Positional Therapy for Obstructive Sleep Apnoea,” Cochrane Database of Systematic Reviews 5, no. 5 (2019): CD010990.

[413] D. Kent, J. Stanley, R. N. Aurora, et al., “Referral of Adults With Obstructive Sleep Apnea for Surgical Consultation: An American Academy of Sleep Medicine Clinical Practice Guideline,” Journal of Clinical Sleep Medicine 17, no. 12 (2021): 2499–2505.

[414] W. Randerath, J. Verbraecken, C. A. L. de Raaff, et al., “European Respiratory Society Guideline on non-CPAP Therapies for Obstructive Sleep Apnoea,” European Respiratory Review 30, no. 162 (2021): 210200.

[415] S. N. Papageorgiou, I. Konstantinidis, A. K. Papadopoulou, et al., “Comparative Efficacy of Non-pharmacological Interventions for Adults With Sleep Apnea: A Systematic Review and Network Meta-analysis,” Sleep Medicine 128 (2025): 130–138.

[416] E. Perger, L. Taranto Montemurro, D. Rosa, et al., “Reboxetine plus Oxybutynin for OSA Treatment: A 1-Week, Randomized, Placebo-Controlled, Double-Blind Crossover Trial,” Chest 161, no. 1 (2022): 237–247.

[417] L. Taranto-Montemurro, L. Messineo, S. A. Sands, et al., “The Combination of Atomoxetine and Oxybutynin Greatly Reduces Obstructive Sleep Apnea Severity. A Randomized, Placebo-controlled, Double-Blind Crossover Trial,” American Journal of Respiratory and Critical Care Medicine 199, no. 10 (2019): 1267–1276.

[418] R. L. Horner, “Targets for Obstructive Sleep Apnea Pharmacotherapy: Principles, Approaches, and Emerging Strategies,” Expert Opinion on Therapeutic Targets 27, no. 7 (2023): 609–626.

[419] H. Hirono, K. Watanabe, K. Hasegawa, M. Kohno, S. Terai, and S. Ohkoshi, “Impact of Continuous Positive Airway Pressure Therapy for Nonalcoholic Fatty Liver Disease in Patients With Obstructive Sleep Apnea,” World Journal of Clinical Cases 9, no. 19 (2021): 5112–5125.

[420] A. Preshy and J. Brown, “A Bidirectional Association between Obstructive Sleep Apnea and Metabolic-Associated Fatty Liver Disease,” Endocrinology and Metabolism Clinics of North America 52, no. 3 (2023): 509–520.

[421] O. Mediano, N. González Mangado, J. M. Montserrat, et al., “International Consensus Document on Obstructive Sleep Apnea,” Archivos De Bronconeumologia 58, no. 1 (2022): 52–68.

[422] K. M. Sarber and R. Dhanda Patil, “Comorbid Insomnia and Sleep Apnea: Challenges and Treatments,” Otolaryngologic Clinics of North America 57, no. 3 (2024): 385–393.

[423] A. Sweetman, L. Lack, M. Crawford, and D. M. Wallace, “Comorbid Insomnia and Sleep Apnea: Assessment and Management Approaches,” Sleep Medicine Clinics 17, no. 4 (2022): 597–617.

[424] A. De Vito, A. Donniacuo, G. Cammaroto, et al., “Maximizing Outcomes by Multimodal Treatment in Obstructive Sleep Apnea: A Systematic Review and Meta-analysis,” European Archives of Oto-Rhino-Laryngology 283, no. 4 (2026): 2093–2106, Published online November 23, 2025.

[425] R. G. S. Andrade, F. M. Viana, J. A. Nascimento, et al., “Nasal vs Oronasal CPAP for OSA Treatment: A Meta-Analysis,” Chest 153, no. 3 (2018): 665–674.

[426] G. Labarca, A. Schmidt, J. Dreyse, J. Jorquera, and F. Barbe, “Telemedicine Interventions for CPAP Adherence in Obstructive Sleep Apnea Patients: Systematic Review and Meta-analysis,” Sleep Medicine Reviews 60 (2021): 101543.

[427] D. Y. Park, J. H. Cho, Y. G. Jung, et al., “Clinical Practice Guideline: Clinical Efficacy of Nasal Surgery in the Treatment of Obstructive Sleep Apnea,” Clinical and Experimental Otorhinolaryngology 16, no. 3 (2023): 201–216.

[428] K. Jeppesen, A. Kørvel-Hanquist, D. L. Wolff, et al., “Patterns and Stability of Long-term Adherence in Continuous Positive Airway Pressure Therapy for Obstructive Sleep Apnea: A Cohort Study,” Sleep & Breathing = Schlaf & Atmung 29, no. 4 (2025): 243.

[429] J. L. Pépin, S. Baillieul, S. Bailly, and R. Tamisier, “New Management Pathways for Follow-up of CPAP-treated Sleep Apnoea Patients Including Digital Medicine and Multimodal Telemonitoring,” Thorax 80, no. 1 (2024): 52–61.

[430] M. Sánchez-de-la-Torre, E. Gracia-Lavedan, I. D. Benitez, et al., “Adherence to CPAP Treatment and the Risk of Recurrent Cardiovascular Events: A Meta-Analysis,” Jama 330, no. 13 (2023): 1255–1265.

[431] Y. Chen, A. I. Alhozgi, and F. R. Almeida, “Dentoskeletal Changes of Long-term Oral Appliance Treatment in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-analysis,” Journal of Prosthodontics 34, no. S1 (2025): 62–79.

[432] C. F. Lin, N. H. Ho, W. L. Hsu, C. H. Lin, Y. H. Wang, and Y. P. Wang, “Effects of Aerobic Exercise and Resistance Training on Obstructive Sleep Apnea: A Systematic Review and Meta-analysis,” Journal of Clinical Sleep Medicine 20, no. 11 (2024): 1839–1849.

[433] I. H. Iftikhar, A. M. Reynolds, E. AlBisher, S. D. Youngstedt, and A. BaHammam, “Aerobic Exercise Training and Obstructive Sleep Apnea: Dose-response Meta-analyses,” Sleep & Breathing = Schlaf & Atmung 28, no. 6 (2024): 2355–2366.

[434] C. Figard, R. Ben Messaoud, and S. Baillieul, “Effect of Sleep Apnoea Interventions on Multiple Health Outcomes: An Umbrella Review of Meta-analyses of Randomised Controlled Trials,” eClinicalMedicine 89 (2025): 103529.

[435] K. Al Oweidat, A. A. Toubasi, R. B. A. Tawileh, H. B. A. Tawileh, and M. M. Hasuneh, “Bariatric Surgery and Obstructive Sleep Apnea: A Systematic Review and Meta-analysis,” Sleep & Breathing = Schlaf & Atmung 27, no. 6 (2023): 2283–2294.

[436] A. Malhotra, R. Grunstein, A. Azarbarzin, et al., “Tirzepatide on Obstructive Sleep Apnea-related Cardiometabolic Risk: Secondary Outcomes of the SURMOUNT-OSA Randomized Trial,” Nature Medicine 32, no. 2 (2026): 653–659.

[437] E. S. Saba, H. Kim, P. Huynh, and N. Jiang, “Orofacial Myofunctional Therapy for Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis,” Laryngoscope 134, no. 1 (2024): 480–495.

[438] E. Pisoni, L. Buttafava, S. Guida, G. Castellini, S. Bargeri, and S. Gianola, “Myofunctional Therapy in Adults and Children with Obstructive Sleep Apnea: An Overview and Re-Analysis of Systematic Reviews,” Journal of Sleep Research 35, no. 3 (2025): e70219, Published online October 4, 2025: e70219.

[439] C. Justribó-Manion, E. A. Sánchez-Romero, J. N. Cuenca-Zaldivar, et al., “Active Conservative Interventions for Obstructive Sleep Apnea: An Umbrella Review and Meta-meta-analysis of Systematic Reviews,” Sleep Medicine 138 (2026): 108665.

[440] A. R. Abreu, D. Stefanovski, S. P. Patil, et al., “Neuromuscular Electrical Stimulation for Obstructive Sleep Apnoea: Comparing Adherence to Active and Sham Therapy,” ERJ Open Research 9, no. 6 (2023): 00474–02023.

[441] B. Kotecha, P. Y. Wong, H. Zhang, and A. Hassaan, “A Novel Intraoral Neuromuscular Stimulation Device for Treating Sleep-disordered Breathing,” Sleep & Breathing = Schlaf & Atmung 25, no. 4 (2021): 2083–2090.

[442] S. Op de Beeck, D. Vena, D. Mann, et al., “Polysomnographic Airflow Shapes and Site of Collapse During Drug-induced Sleep Endoscopy,” European Respiratory Journal 63, no. 6 (2024): 2400261.

[443] C. R. John, S. Gandhi, A. R. Sakharia, and T. T. James, “Maxillomandibular Advancement Is a Successful Treatment for Obstructive Sleep Apnoea: A Systematic Review and Meta-analysis,” International Journal of Oral and Maxillofacial Surgery 47, no. 12 (2018): 1561–1571.

[444] T. J. Diemer, D. P. Nanu, S. A. Nguyen, B. Ibrahim, T. A. Meyer, and M. Abdelwahab, “Maxillomandibular Advancement for Obstructive Sleep Apnea in Patients with Obesity: A Meta-Analysis,” Laryngoscope 135, no. 2 (2025): 507–516.

[445] P. J. Strollo, R. J. Soose, J. T. Maurer, et al., “Upper-airway Stimulation for Obstructive Sleep Apnea,” New England Journal of Medicine 370, no. 2 (2014): 139–149.

[446] B. T. Woodson, K. P. Strohl, R. J. Soose, et al., “Upper Airway Stimulation for Obstructive Sleep Apnea: 5-Year Outcomes,” Otolaryngology - Head and Neck Surgery 159, no. 1 (2018): 194–202.

[447] M. R. Bonsignore, F. Fanfulla, P. Ingrao, et al., “Management Options for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea,” Expert Review of Respiratory Medicine 19, no. 4 (2025): 325–345.

[448] J. L. Pépin, P. Lehert, R. Ben Messaoud, et al., “Comparative Efficacy, Safety and Benefit/Risk of Alerting Agents for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea: A Network Meta-analysis,” EClinicalMedicine 76 (2024): 102843.

[449] D. Testelmans, P. Lehert, J. Asin, J. Imschoot, C. Caussé, and J. L. Pépin, “Efficacy and Safety of Pitolisant in Residual Excessive Daytime Sleepiness for Patients With Obstructive Sleep Apnea Adhering to Continuous Positive Airway Pressure Therapy in the HAROSA Studies: An Individual Patient Meta-analytical Approach,” Sleep Medicine 129 (2025): 1–7.

[450] P. Tanayapong, V. Tantrakul, S. Liamsombut, et al., “Comparative Efficacy and Safety of Multiple Wake-Promoting Agents for the Treatment of Residual Sleepiness in Obstructive Sleep Apnea Despite Continuous Positive Airway Pressure: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials,” CNS Drugs 39, no. 6 (2025): 527–544.

[451] M. A. Reveyaz, C. Peyronnel, Q. Boete, et al., “Oxidative and Inflammatory Mechanisms Induced by Intermittent Hypoxia Leading to Vascular Alterations in Rodents: A Systematic Review and Meta-analysis,” Oxidative Medicine and Cellular Longevity 2026 (2026): 9967028, Published online 2026.

[452] R. Cortese, K. Cataldo, M. Badran, et al., “Intermittent Hypoxia Mimicking Sleep Apnea Induces Systemic and Tissue-specific Epigenetic Changes and p16-mediated Cellular Senescence Underlying Vascular Dysfunction,” Research Square (2026): rs.3.rs–9371471, Preprint posted online 2026.

[453] P. J. Strollo, R. Farkas, L. Taranto-Montemurro, et al., “Aroxybutynin and Atomoxetine (AD109) for Obstructive Sleep Apnea: A Randomized Phase 3 Trial (SynAIRgy),” American Journal of Respiratory and Critical Care Medicine 212, no. 7 (2026): 1569–1584.

[454] L. Taranto-Montemurro, S. R. Patel, P. J. Strollo Jr., et al., “Aroxybutynin and Atomoxetine (AD109) for the Treatment of Obstructive Sleep Apnea: Rationale, Design and Baseline Characteristics of the Phase 3 Clinical Trials,” Contemporary Clinical Trials Communications 47 (2025): 101538.

[455] W. Randerath, L. Grote, K. Stenlöf, et al., “Sultiame Once per Day in Obstructive Sleep Apnoea (FLOW): A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-finding, Phase 2 Trial,” The Lancet 406, no. 10514 (2025): 1983–1992.

[456] C. Kanu, S. Shinde, S. Chakladar, et al., “Effect of Tirzepatide Treatment on Patient-reported Outcomes Among SURMOUNT-OSA Participants With Obstructive Sleep Apnea and Obesity,” Sleep Medicine 134 (2025): 106719.

[457] C. H. Fung, S. Mak, G. Ash, et al., “Augmenting Management of Obstructive Sleep Apnea With Consumer Wearable Devices to Increase Use of Positive Airway Pressure Therapy: A Pilot Randomized Trial,” SLEEPJ 49, no. 4 (2026): zsaf342.

[458] F. Fank, R. S. Artismo, A. R. Rocha, et al., “Effects of Combined Exercise and Sleep Hygiene on Obstructive Sleep Apnea Severity in Older Adults: A Randomized Controlled Trial,” Sleep Medicine 144 (2026): 108967.

[459] J. R. V. De Almeida, B. Q. Farah, J. L. P. Aguiar, et al., “Effects of Resistance Training on Obstructive Sleep Apnea Severity: A Randomized Controlled Trial,” Sleep Medicine 142 (2026): 108879.

[460] C. Rodríguez-Alcalá, L. Rodríguez-Alcalá, and J. M. Ignacio-García, “Telemedicine-delivered Myofunctional Therapy Remodels Upper Airway Anatomy in Obstructive Sleep Apnea: A Prospective Controlled Study,” Journal of Clinical Sleep Medicine 22, no. 1 (2026): 12.

[461] J. T. Colpani, Y. H. Ou, A. M. Kosasih, et al., “Mandibular Advancement Device versus CPAP in Severe Obstructive Sleep Apnea,” Journal of Dental Research 105, no. 1 (2026): 112–119.

[462] G. Iannella, S. Terranova, M. Brunori, et al., “Effectiveness of Drug-induced Sleep Endoscopy in Improving Patients Selection and Outcomes of Mandibular Advancement Device Therapy for Obstructive Sleep Apnea: A Multicenter Case-control Study,” American Journal of Otolaryngology 47, no. 1 (2026): 104740.

[463] A. Tangutur, P. K. Yu, M. Basner, B. T. Keenan, and R. C. Dedhia, “Subjective and Objective Measures of Sleep-related Function From the Cardiovascular Endpoints for Obstructive Sleep Apnea With Twelfth Cranial Nerve Stimulation (CARDIOSA-12) Trial: Sleep-related Functional Outcomes in CARDIOSA-12,” Journal of Clinical Sleep Medicine 22, no. 1 (2026): 45.

[464] B. T. Woodson, D. T. Kent, C. Huntley, et al., “Bilateral Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea: A Nonrandomized Clinical Trial,” Journal of Clinical Sleep Medicine 21, no. 11 (2025): 1883–1891.

[465] H. Cheng, L. Deng, Z. Meng, et al., “Efficacy and Safety of Solriamfetol on Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea in China: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial,” CNS Drugs 40, no. 1 (2026): 83–98.

[466] S. Mancuso, D. Caratozzolo, A. Libra, et al., “Randomized Controlled Trial on the Effect of a 12-month Telemedicine Program in Patients With Obstructive Sleep Apnea on Continuous Positive Airway Pressure Treatment,” Respiratory Medicine 250 (2025): 108524.

[467] L. Pinilla, N. Esmaeili, G. Labarca, et al., “Hypoxic Burden to Guide CPAP Treatment Allocation in Patients With Obstructive Sleep Apnoea: A Post Hoc Study of the ISAACC Trial,” European Respiratory Journal 62, no. 6 (2023): 2300828.

[468] M. Hasanain, A. Akram, A. Kabir, et al., “Diagnostic Value of Wearable and Contactless Technologies for Detecting Obstructive Sleep Apnea: A Systematic Review and Meta-analysis,” Sleep & Breathing = Schlaf & Atmung 29, no. 6 (2025): 368.

[469] A. Osa-Sanchez, J. Ramos-Martinez-de-Soria, A. Mendez-Zorrilla, I. O. Ruiz, and B. Garcia-Zapirain, “Wearable Sensors and Artificial Intelligence for Sleep Apnea Detection: A Systematic Review,” Journal of Medical Systems 49, no. 1 (2025): 66.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.